Attorney Docket No.: **P0825BC3**
PATENT

CERTIFICATION UNDER 37 CFR 1.10

TB 835479953: Express Mail Number — April 30, 1997: Date of Deposit

I hereby certify that this Transmittal of Filing Under 37 CFR 1.60(b) and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Janet Tse

Janet Tse

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PRIOR APPLICATION Serial No. 08/447,291
PRIOR APPLICATION Examiner: V. Ryan
Art Unit: 1802

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

TRANSMITTAL OF FILING UNDER 37 CFR 1.60(b)

This is a request for filing a

X continuation
____ divisional

application under 37 CFR 1.60, of pending prior application Serial No. 08/447,291 filed on 22 May 1995

of **Jeffrey L. Cleland, Amy Lim, Michael F. Powell**

for **METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES**

1. Copy of Prior Application as Filed Which is Attached

X I hereby verify that the attached papers are a true copy of what is shown in my records to be the above-identified prior application, including the oath or declaration originally filed (37 CFR 1.60).

The copy of the papers of prior application as filed which are attached are as follows:

64 pages of specification
3 pages of claims
1 page(s) of abstract
14 sheet(s) of drawings

2 pages of declaration and power of attorney

(If the copy of the declaration being filed does not show applicant's signature, because the attorney's records do not contain a copy of the signed declaration actually filed for the application, indicate thereon that it was signed and complete the following:)

_____ in accordance with the indication required by 37 CFR 60(b), my records reflect that the original signed declaration showing applicant's signature was filed on

_____ the amendment referred to in the declaration filed to complete the prior application and I hereby state, in accordance with the requirements of 37 CFR 1.60(b), that this amendment did not introduce new matter therein.

2. Amendments

__X__ Cancel in this application original claims 2, 3 and 10-22 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

__X__ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

3. Petition for Suspension of Prosecution for the Time Necessary to File an Amendment

_____ There is provided herewith a Petition To Suspend Prosecution for the Time Necessary to File an Amendment (New Application Filed Concurrently).

4. A Letter to Draftsman with Proposed Drawing Correction Under 37 CFR §1.123 and MPEP §§608.02(Q) and (R) and Corrected Figures 5 and 6 are submitted herewith.

5. Fee Calculation (37 CFR 1.16)

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					$ 770.00
Total Claims	12	- 22 =	0	X $22.00	$0.00
Independent Claims	1	- 4 =	0	X $80.00	$0.00
__	Multiple dependent claim(s), if any			+ 260.00	$0.00
				Filing Fee Calculation	$770.00

6. Priority -- 35 U.S.C. 119

_____ Priority of application Serial No. filed on in is claimed under 35 U.S.C. 119.

_____ The certified copy has been filed on in prior U.S. application Serial No. , which prior application was filed on .

_____ certified copy will follow.

7. Relate Back -- 35 U.S.C. 120

__X__ Amend the specification by inserting before the first line the sentence:

--This is a

__X__ continuation
_____ divisional

of co-pending application(s)

__X__ Serial No. 08/447,291 filed on 22 May 1995, which is a continuation of Serial No. 08/365,986 filed on 28 December 1994, which is a continuation of Serial No. 08/143,555 filed on 25 October 1993, now abandoned, which applications are incorporated herein by reference and to which applications priority is claimed under 35 USC §120.--

_____ International Application filed on , which designated the U.S., and which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--

8. Inventorship Statement
[complete appropriate items (a) and (b) below]

(a) With respect to the prior copending U.S. application from which this application claims benefit under 35 USC 120 the inventor(s) in this application are:
__X__ the same
_____ less than those named in the prior application and it is requested that the following inventor(s) identified above for the prior application be deleted:

(b) The inventorship for all the claims in this application are
__X__ the same
_____ not the same, and an explanation, including the ownership of the various claims at the time the last claimed invention was made, is submitted.

9. Assignment

__X__ the prior application is assigned of record to GENENTECH, INC., recorded on 24 January 1994 at Reel 6830, Frame 0251.

_____ an assignment of the invention to is attached. (Attach with Recordation Form).

10. Fee Payment Being Made at This Time

ATTACHED

__X__	basic filing fee	$ 770.00
_____	recording assignment ($40.00; 37 CFR 1.21(h))	$
_____	processing and retention fee ($130.00; 37 CFR 1.53(d) and 1.21(l))	$
	TOTAL FEE ENCLOSED:	$ 770.00

11. Method of Payment of Fees

__X__ charge Account No. 07-0630 in the amount $ 770.00

__X__ A duplicate of this request is attached.

12. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630.

13. Power of Attorney

The power of attorney in the prior application is to:

Walter E. Buting - Reg. No. 23,092
Ginger R. Dreger - Reg. No. 33,055
Janet E. Hasak - Reg. No. 28,616
Sean A. Johnston - Reg. No. 35,910
Jeffrey S. Kubinec - Reg. No. 36,575
Daryl B. Winter - Reg. No. 32,637

a. __X__ The power appears in the original papers in the prior application.

b. _____ The power does not appear in the original papers, but was filed on (copy enclosed).

c. _____ A new power has been executed and is attached.

d. __X__ Address all future communications to:

GENENTECH, INC.
Attn: Jeffrey S. Kubinec
460 Point San Bruno Boulevard
South San Francisco, CA 94080-4990
(415) 225-8228

[Item d may only be completed by applicant or agent of record].

14. Maintenance of Copendency of Prior Application
*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

_____ A petition, fee and response has been filed to extend the term in the pending prior application until

__X__ A copy of the petition for extension of time in the ***prior*** application is attached.

15. Conditional Petitions for Extension of Time in Prior Application

_____ A conditional petition for extension of time is being filed in the pending prior application

_____ A copy of the conditional petition for extension of time in the ***prior*** application is attached.

16. Abandonment of Prior Application *(if applicable)*

_____ Please abandon the prior application at a time when the prior application is pending or when the petition for extension of time or to revive in that application is granted and when

this application is granted a filing date so as to make this application copending with said prior application. At the same time please add the words "now abandoned" to the amendment to the specification set forth in 7. above.

Dated: April 30, 1997

Jeffrey S. Sabmec
Reg. No. 36,575

GENENTECH, INC.
460 Point San Bruno Blvd.
South San Francisco, CA 94080-4990
(415) 225-8228

____ Inventor
____ Assignee of complete interest
____ Person authorized to sign for assignee
_X_ Attorney or agent of record
____ Filed under rule 34(a)

Patent Docket P0825BC2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Cleland et al. Serial No.: 08/447,291 Filed: 22 May 1995 For: METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES	Group Art Unit: 1802 Examiner: V. Ryan CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on April 30, 1997 Janet Tse

PETITION AND FEE FOR ONE MONTH EXTENSION OF TIME
(37 CFR 1.136(a))

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants petition the Commissioner of Patents and Trademarks to extend the time for filing Appellants' Brief for one month from April 6, 1997 up to and including May 6, 1997. The extended time for response does not exceed the statutory period.

Please charge Deposit Account No. 07-0630 in the amount of $110 to cover the cost of the extension. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

Respectfully submitted,
GENENTECH, INC.

Date: April 30, 1997 By: _____
Jeffrey S. Kubinec
Reg. No. 36,575

460 Pt. San Bruno Blvd.
So. San Francisco, CA 94080-4990
Phone: (415) 225-8228
Fax: (415) 952-9881

Express Mail No. TB 835479953
Mailed April 30, 1997
Patent Docket P0825BC3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Continuation of: Jeffrey L. Cleland et al. Serial No.: 08/447,291 Filed: 22 May 1995 For: METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES	Group Art Unit: To be assigned Examiner: To be assigned

PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

The present application is a continuation of U.S. Serial No. 08/447,291 under the continuation procedure of 37 C.F.R. § 1.60. Prior to the examination of the application on its merits, please consider and enter the following amendments and remarks. Applicants submit herewith a Letter to the Draftsman with proposed drawing corrections under 37 C.F.R. § 1.123 and MPEP §§608.02 (q) and (r).

IN THE SPECIFICATION

Please amend the specification as follows:

Prior to the first sentence and after the Title, please insert the following sentence:

--This application is a continuation of U.S. Serial No. 08/447,291 filed May 22, 1995, which is a continuation of U.S. Serial No. 08/365,986, filed December 28, 1994, now abandoned, which is a continuation of U.S. Serial No. 08/143,555 filed

October 25, 1993, now abandoned.--

IN THE CLAIMS

Please cancel claims 2, 3 and 10-22 without prejudice.

Please amend the claims as follows:

1. (amended) A composition comprising an essentially homogenous population of poly(D-L-lactide-co-glycolide) (PLGA) polymer microspheres encapsulating an aqueous antigen, wherein in said population

(a) the volume of aqueous antigen incorporated into the polymer is equal to or less than 1 milliliter per 3 grams of polymer;

(b) the ratio of lactide to glycolide in the polymer is from about 100:[1] 0 to 50:50 [1:100] weight percent;

(c) the inherent viscosity of PLGA polymers used in the microspheres is about 0.1 to 1.2 dL/g;

(d) the median diameter of the microspheres is from about 20 to 100 μm; and

(e) the antigen is released from the microspheres in a triphasic pattern characterized by a first phase, wherein about 0.5 to 30 percent [95%] of the antigen is released from the microspheres over a period of about 1 day [in an initial burst], a second phase, beginning at the completion of the first phase wherein less than 10 percent of the antigen [about 0 to 50%] is released from the microspheres over a period of between about 30 [1] to 180 days, and a third phase beginning at the completion of the second phase wherein the remaining antigen is released from the microspheres over a period of about 10 to 30 days [in a second burst after about 1 to 180 days].

4. (reiterated) The composition of claim 1 wherein the median diameter of the microspheres is about 30 μm.

5. (reiterated) The composition of claim 1 further comprising an adjuvant.

6. (reiterated) The composition of claim 5 wherein the adjuvant is encapsulated in the PLGA microspheres.

7. (reiterated) The composition of claim 5 wherein the adjuvant is coencapsulated with the antigen in the microspheres.

8. (reiterated) The composition of claim 5 wherein the adjuvant is QS21.

9. (reiterated) The composition of claim 1 further comprising a soluble antigen.

Please add the following new claims:

--23. The composition according to claim 1 wherein the second phase is over a period of about 30 days.

24. The composition according to claim 1 wherein the second phase is over a period of about 60 days.

25. The composition according to claim 1 wherein the second phase is over a period of about 90 days.

26. The composition according to claim 1 wherein the second phase is over a period of about 120 days.

27. The composition according to claim 1 wherein the second phase is over a period of about 180 days.--

REMARKS

Applicants request the amendment of claim 1, the cancellation of claims 2, 3 and 10-22 as well as the addition of new claims 23-27 so that upon entry of the instant amendment, claims 1, 4-9 and 23-27 will be pending in this application. Support for the amended and new claims is replete in the application and claims as filed. Support for the amended recitation, "essentially homogenous population" can be found throughout the application including, for example, at page 16, line 27 through page 17, line 32, page 23, lines 27-31 and page 24, lines 17-29 (populations). Support for an "aqueous" antigen comes at least from page 17, lines 8-9. Support for recitation "(a)" comes from at least, pages 35, line 33 through page 36, line 2, page 37, lines 37-38, page 39, lines 10-30 and page 55, lines 40-44. Support for the timing of the first, second and third phases of release can be found throughout the specification including at, for example, page 47, lines 10-15 (a period of 180 days beginning at the completion of the initial burst), Figure 8 (the third phase occurs at the completion of the second phase and generally endures for a period of about between one and thirty days) page 59, lines 16-18, for example, as well as, page 45, lines 43-45; page 47, lines 10-11; pages 35, line 33 through page 36, line 2; page 37, lines 37-38; page 39, lines 10-30 and page 55, lines 40-44. Support for the period of, for example, one, two, three, four and six month periods of release comes from, for example page 45, line 45 and page 47, line 11, as well as, for example, page 46, line 26 and page 7, line 2 (60, 70, 90, 100, and 180 days). Furthermore, the description and Example sections clearly describe how to make and use microsphere populations having a second phase enduring for a period of one through 6 months (see page 47, for example). A particular description of "0.5 to about 30 percent" comes from, for example, page 43, lines

33-34, Table 5, as well as the claims as filed and the extensive discussion of parameters which affect the amount and duration of the "initial burst" as well as the actual demonstrations in Tables 2-5. For both written and enabling support for the period of about 1 to two days, the Examiner attention is drawn to those same sections indicated above as well as Figure 8 and the data accompanying that Figure.

Applicants respectfully seek the approval of the Examiner in making the corrections to Figures 5 and 6 indicated in the separate letter to the draftsman with proposed drawing correction under 37 C.F.R. §1.123 and MPEP §§608.02(q) and (r) which accompanies this amendment.

CONCLUSION

Applicants respectfully request that the foregoing amendments be considered and entered in the file history of the above-identified application. It is submitted that the application and claims are in condition for allowance. It is therefore earnestly solicited that such a favorable disposition is made. The Examiner is invited to telephone Jeffrey S. Kubinec, Esq. (Reg. No. 36,575) at (415) 225-8228 if deemed helpful to clarify and advance prosecution.

Respectfully submitted,

GENENTECH, INC.

Date: April 25, 1997 By: _____

Jeffrey S. Kubinec
Reg. No. 36,575

460 Pt. San Bruno Blvd.
So. San Francisco, CA 94080-4990
Phone: (415) 225-8228
Fax: (415) 952-9881

Express Mail No. TB 835479953
Mailed April 30, 1997
Patent Docket P0825BC3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Jeffrey L. Cleland et al. Serial No.: To Be Assigned Filed: 30 April 1997 For: METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES	Group Art Unit: To Be Assigned Examiner: To Be Assigned

LETTER TO DRAFTSMAN WITH PROPOSED DRAWING CORRECTION
UNDER 37 C.F.R. §1.123 AND MPEP §§608.02(Q) AND (R)

Assistant Commissioner of Patents
Washington, D.C. 20231
Attention: Official Draftsman

Sir:

Pursuant to 37 CFR §1.123 and MPEP §§608.02(q) and (r), applicants hereby propose corrections to Figure 5 and Figure 6 as indicated on the enclosed sketches in permanent red ink. Figure 5, as originally filed is correctly Figure 6. Likewise, Figure 6 as originally filed is correctly Figure 5.

Applicants have recently become aware of an inadvertent reversal of the Figure designations in the above noted Figures. The proposed amendments to the drawing do not incorporate new matter into the specification as filed since the description of the Figures at page 9, lines 6-21 correctly describes the Figures. Additionally, it is clear from the Figures themselves and the written description at page 43, lines 4-6, i.e., "microspheres

produced ... were cracked and broken after lyophilization (Figure 5)"; and at page 43, lines 15-17, i.e., "the microspheres were not broken or cracked ... (Figure 6)", that the proper designations of the Figures are as described in the instant amendment.

Therefore, applicants respectfully seek the approval of the Examiner in making the above noted corrections to the Figures.

This letter is submitted in duplicate in accordance with MPEP §608.02(q).

Respectfully submitted,

GENENTECH, INC.

Date: April 30, 1996

By: [signature]

Jeffrey S. Kubinec
Reg. No. 36,575

460 Pt. San Bruno Blvd.
So. San Francisco, CA 94080-4990
Phone: (415) 225-8228
Fax: (415) 952-9881



Figure ~~5~~ 6

Figure 6 5

Express Mail No. TB 835479953
Mailed April 30, 1997
Patent Docket P0825BC3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Jeffrey L. Cleland et al. Serial No.: To Be Assigned Filed: 30 April 1997 For: METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES	Group Art Unit: To Be Assigned Examiner: To Be Assigned

LETTER TO DRAFTSMAN WITH PROPOSED DRAWING CORRECTION UNDER 37 C.F.R. §1.123 AND MPEP §§608.02(Q) AND (R)

Assistant Commissioner of Patents
Washington, D.C. 20231
Attention: Official Draftsman

Sir:

Pursuant to 37 CFR §1.123 and MPEP §§608.02(q) and (r), applicants hereby propose corrections to Figure 5 and Figure 6 as indicated on the enclosed sketches in permanent red ink. Figure 5, as originally filed is correctly Figure 6. Likewise, Figure 6 as originally filed is correctly Figure 5.

Applicants have recently become aware of an inadvertent reversal of the Figure designations in the above noted Figures. The proposed amendments to the drawing do not incorporate new matter into the specification as filed since the description of the Figures at page 9, lines 6-21 correctly describes the Figures. Additionally, it is clear from the Figures themselves and the written description at page 43, lines 4-6, i.e., "microspheres

produced ... were cracked and broken after lyophilization (Figure 5)"; and at page 43, lines 15-17, i.e., "the microspheres were not broken or cracked ... (Figure 6)", that the proper designations of the Figures are as described in the instant amendment.

Therefore, applicants respectfully seek the approval of the Examiner in making the above noted corrections to the Figures.

This letter is submitted in duplicate in accordance with MPEP §608.02(q).

Respectfully submitted,

GENENTECH, INC.

Date: April 30, 1996

By: ______________________

Jeffrey S. Kubinec
Reg. No. 36,575

460 Pt. San Bruno Blvd.
So. San Francisco, CA 94080-4990
Phone: (415) 225-8228
Fax: (415) 952-9881

Patent Docket No. 80825BC3
Express Mail No.: TB 835479953
Date Mailed: 30 April 1997

Patent Docket No. 825B
Express Mail No.: TB 383 846 64X
Date Mailed: 25 October 1993

METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

This invention relates to the microencapsulation of antigens for use as therapeutic or prophylactic vaccines.

DESCRIPTION OF BACKGROUND AND RELATED ART

Traditional immunization protocols typically require multiple exposures of the patient to the antigen, usually by injections of a vaccine formulation at intervals of weeks or months. There is a need in the art to deliver the antigen of interest to the patient in a formulation which releases the antigen in bursts spaced days to months apart so as to reduce the need for multiple injections. The initial burst of antigen can be augmented by the addition of soluble antigen to the vaccine formulation. The efficacy of such vaccines can be improved further by the addition of an adjuvant, in soluble and/or microencapsulated form.

Recombinant subunit vaccines have been produced for a variety of viruses, including herpes, malaria, hepatitis, foot and mouth disease, and HIV. Currently, gp120 is considered to be a good candidate for an HIV subunit vaccine, because: (i) gp120 is known to possess the CD4 binding domain by which HIV attaches to its target cells, (ii) HIV infectivity can be neutralized in vitro by antibodies to gp 120, (iii) the majority of the in vitro neutralizing activity

present in the serum of HIV infected individuals can be removed with a gp120 affinity column, and (iv) the gp120/gp41 complex appears to be essential for the transmission of HIV by cell-to-cell fusion. Recombinant subunit vaccines are described in Berman et al., PCT/US91/02250 (published as number WO91/15238 on 17 October 1991). See also, e.g., Hu et al. Nature 328:721-724, 1987 (vaccinia virus-HIV env recombinant vaccine); Arthur et al. J. Virol. 63(12): 5046-5053, 1989) (purified gp120); and Berman et al. Proc. Natl. Acad. Sci. USA 85:5200-5204, 1988 (recombinant envelope glycoprotein gp120). There have been suggestions in the literature of making a vaccine which is a combination of various HIV isolates or isolate subunits. See e.g. Berman et al., PCT/US91/02250 (published as number WO91/15238 on 17 October 1991) and Rusche et al., PCT/US89/04302 (published as number WO90/03984 on 19 April 1990).

Different antigens can be combined in the formulation, either within the same microspheres or as a mixture of microspheres, to provide a multivalent or multitarget vaccine. Furthermore, as microspheres can be designed to release a second burst of antigen and/or adjuvant ("autoboost") when desired, a single vaccine preparation can be designed so as to mix populations of microspheres which release their bursts of antigens and/or adjuvants at multiple prescribed intervals when such multiple challenges with antigen and/or adjuvant are desired.

Preferred adjuvants for use in the compositions and methods of the instant invention include saponins and their derivatives. For example, U.S. Patent No. 5,057,540 discloses the uses of Quillaja saponins, a mixture of striterpene glycosides extracted from the bark of the tree *Quillaja saponaria*, as immune adjuvants. Saponins can be isolated from other plants, such as soybeans (U.S. Patent No. 4,524,067). White et al. (Immunology of Proteins and

Peptides VI, ed. M. Z. Atassi, Plenum Press, NY, 1991) disclose the use of QS21 as an adjuvant for a T-independent antigen. Wu et al. (J. Immunol. 148:1519-1525, 1992) disclose the use of QS21 as an adjuvant for the HIV-1 envelope protein gp160 in mice. Newman et al. (AIDS Research and Human Retroviruses 8:1413-1418, 1992) disclose the use of QS21 as an adjuvant for the HIV-1 envelop protein gp160 in rhesus macaques. Kensil et al. (J. Am. Vet. Med. Assoc. 199:1423-1427, 1991) disclose the use of QS21 as an adjuvant for the feline leukemia virus subgroup A gp70 protein.

Polymer matrices for forming microspheres are also described in the literature. For example, Chang et al. (Bioengineering 1:25-32, 1976) disclose semipermeable microspheres containing enzymes, hormones, vaccines, and other biologicals. U.S. Patent No. 5,075,109 discloses a method of potentiating an immune response by administering a mixture of at least two populations of microspheres containing bioactive agents such that one of the microsphere populations is sized between about 1 to 10 μm. U.S. Patent No. 4,293,539 discloses a controlled release formulation of an active ingredient in a copolymer derived from about 60 to 95 weight percent lactic acid and about 40 to about 4 weight percent glycolic acid. U.S. Patent No. 4,919,929 discloses the administration of an antigenic substance in a shaped structure of a biocompatible matrix material. U.S. Patent No. 4,767,628 discloses composition comprising an active, acid stable polypeptide and a polylactide, which when placed in an aqueous physiological environment release the polypeptide at an approximately constant rate in an essentially monophasic manner. U.S. Patent No. 4,962,091 discloses a microsuspension of water soluble macromolecular polypeptides in a polylactide matrix. U.S. Patent Nos. 4,849,228 and 4,728,721 disclose a biodegradable, high molecular weight polymer characterized in that the content of water-soluble low molecular weight compounds, as calculated

on the assumption that such compounds are monobasic acids, is less than 0.01 mole per 100 grams of high molecular weight polymer. U.S. Patent Nos. 4,902,515 and 4,719,246 disclose polylactide compositions containing segments of poly(R-lactide) interlocked with segments of poly(S-lactide). U.S. Patent No. 4,990,336 discloses a multiphasic sustained release system comprising allergen extract encapsulated in microspheres of bioerodible encapsulating polymer which permits a sustained, multiphasic release of the allergen. This system includes a first portion of allergen extract that upon injection is capable of being released in a manner whereby initial allergenicity is minimized to producing a mild local reaction similar to that normally observed with low doses of conventional allergen administration, and secondary portions of allergen extract that provide a substantially higher level of allergen extract in doses that could provide a serious reaction in the patient, but for the release of the first portion of allergen extract. U.S. Patent No. 4,897,268 discloses a microcapsule delivery system wherein the ingredients are encapsulated in biodegradable copolymer excipients of varying mole ratios, such that delivery of the ingredients occurs at a constant rate over a prolonged period of time.

Various water-in-oil emulsions are described in the literature. Thus, for example, U.S. Patent Nos. 4,917,893 and 4,652,441 disclose a microcapsule produced by preparing a water-in-oil emulsion comprising an inner aqueous layer containing a water-soluble drug, a drug-retaining substance, and an oil layer containing a polymer substance; the inner or aqueous layer is thickened or solidified to a viscosity of not lower than about 5000 centipoises. The resulting emulsion is subjected to in-water drying. U.S. Patent No. 4,954,298 discloses the production of microcapsules by preparing a water-in-oil emulsion composed of a water-soluble drug-containing solution as the inner aqueous phase and a polymer-

containing solution as the oil phase, dispersing the emulsion in an aqueous phase and subjecting the resulting water-in-oil-in-water emulsion to an in-water drying, wherein the viscosity of the water-in-oil emulsion used in preparing the water-in-oil-in-water emulsion is adjusted to about 150 to about 10,000 centipoises.

Accordingly, it is an object of the invention to provide a microencapsulated vaccine formulation, which can include one or more adjuvants.

It is another object of the invention to provide a vaccine for the prophylaxis and/or treatment of HIV infection.

It is a further object of the invention to provide a method for producing microspheres.

These and other objects will become apparent to those of ordinary skill in the art.

SUMMARY OF THE INVENTION

Accordingly, the instant invention provides for the delivery of an antigen or antigens to a host in a microsphere format. The antigen or antigens can be delivered concomitantly with an adjuvant packaged within the same microsphere or in some other delivery format; alternatively, an adjuvant can be provided before or after the antigen-containing microspheres, or be packaged independently in microspheres. The microspheres of the instant invention release the antigen and/or adjuvant in three phases: an initial burst, a slow release, and a second burst. Preferred adjuvants for use in the compositions and methods of the instant invention include saponins and their derivatives.

One aspect of the invention is a composition comprising poly(D-L-lactide-co-glycolide) (PLGA) microspheres encapsulating an antigen, wherein

the ratio of lactide to glycolide is from about 100:1 to 1:100 weight percent;

the inherent viscosity of PLGA polymers used in the microspheres is about 0.1 to 1.2 dL/g;

the median diameter of the microspheres is from about 20 to 100 μm; and

the antigen is released from the microspheres in a triphasic pattern, wherein about 0.5 to 95% of the antigen is released in an initial burst, about 0 to 50% is released over a period of about 1 to 180 days, and the remaining antigen is released in a second burst after about 1 to 180 days.

Another aspect of the invention is a composition for use as a vaccine comprising antigen encapsulated in PLGA microspheres, and soluble antigen.

Another aspect of the invention is a composition for use as a vaccine comprising about one to 100 antigens encapsulated in a mixture of about two to 50 PLGA microsphere populations, wherein

the ratio of lactide to glycolide is from about 100:1 to 1:100 weight percent;

the inherent viscosity of PLGA polymers used in the microspheres is about 0.1 to 1.2 dL/g;

the median diameter of the microspheres is from about 20 to 100 μm; and

the antigen is released from the microspheres in a triphasic pattern, wherein about 0.5 to 95% of the antigen is released in an initial burst, about 0 to 50% is released over a period of about 1 to 180 days, and the remaining antigen is released in a second burst in one microsphere population after about 1 to 30 days, in a second microsphere population

after about 30 to 90 days, and in additional microsphere populations after about 90 to 180 days.

Another aspect of the invention is a method for encapsulating antigen in microspheres, comprising

(a) dissolving PLGA polymer in an organic solvent to produce a solution;

(b) adding antigen to the solution of (a) to produce a PLGA-antigen mixture comprising a first emulsion;

(c) adding the mixture of step (b) to an emulsification bath to produce microspheres comprising a second emulsion; and

(d) hardening the microspheres of step (b) to produce hardened microspheres comprising encapsulated antigen.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram depicting the bulk erosion process for PLGA microspheres. PLGA microspheres are typically hydrated prior to administration. Water hydrolyzes the ester linkages in the PLGA backbone as shown in the inset diagram resulting in a bulk erosion of the polymer over time. The rate of hydrolysis depends upon the water content of the microspheres, the solvent environment (e.g., pH), and the temperature. The number of scissions in the polymer backbone required to cause fragmentation of the microspheres is dependent on the polymer molecular weight.

Figure 2 is a diagram depicting in vivo degradation rate for PLGA polymers modified from Miller et al. (J. Biomed. Mater. Res. 11:711-719, 1977). The X-axis represents the relative ratio of either lactide or glycolide for each PLGA. The slowest degradation rates for a given polymer molecular weight occur for the polylactic acid (PLA) and polyglycolic acid (PGA) systems. The fastest degradation rate was achieved with PLGA containing an equal molar ratio of lactide

and glycolide. The in vivo half-time to complete degradation was measured by histology studies in rats.

Figure 3 is a diagram depicting the microsphere production process using a double emulsion method. PLGA polymers at different molecular weights were added to methylene chloride and allowed to dissolve. A solution of MN rgp120 was then injected into the methylene chloride while homogenizing. The homogenized solution was added to a polyvinyl alcohol (PVA) solution. The PVA solution was saturated with methylene chloride (1.5% v/v) for some experiments. The PVA and polymer solutions were mixed in a one-liter fermenter to form the final water-in-oil-in-water emulsion. The resulting microspheres were then transferred to the hardening bath which contained an excess of water to extract the remaining methylene chloride. The hardened microspheres were then washed and dried by lyophilization or low temperature (5° C) nitrogen (fluidized bed) or vacuum drying to produce the final microspheres for in vivo and in vitro analysis. The items listed in italics are the variables for each process step.

Figure 4 is a diagram depicting an air lift (fluidized bed) drying system for nitrogen drying of PLGA microspheres. (a) Slurry from a diafiltration unit is pumped into the chamber with the upper piston (b) above the inlet. The upper piston is then moved down and the excess liquid is pressurized out by applying nitrogen through the upper inlet (c). The airflow is then redirected to suspend the microspheres by purging with nitrogen through the lower inlet (d) and releasing the nitrogen through the upper inlet (c). After complete drying (1 to 2 days), the dry powder is removed by placing a collection vessel (side arm flask, not shown) on the outlet, moving the upper piston (b) above the outlet, and applying nitrogen pressure at the lower inlet (d) while pulling a vacuum on the collection vessel.

Alternatively, the drier can be designed with both pistons welded in place and the upper piston located above the inlet for the slurry. After pumping in the slurry, the slurry outlet side arm is then sealed by a valve during drying.

Figure 5 is a scanning electron micrograph of microspheres prepared with 12 kDa (50:50 lactide:glycolide) PLGA from Boehringer Ingelheim (BI) at room temperature with excess methylene chloride in the second emulsion. The final drying step was lyophilization. The microspheres had a protein loading of 1% w/w (8% efficiency) and an initial burst of greater than 50% of encapsulated material.

Figure 6 is a scanning electron micrograph of microspheres prepared with 12 kDa (50:50 lactide:glycolide) PLGA with preferred process conditions. These microspheres were prepared at low temperature (0°C) without excess methylene chloride in the second emulsion. The final drying step was lyophilization. The microspheres had a protein loading of 3% w/w (58% efficiency) and an initial burst of greater than 50% of encapsulated material.

Figure 7 is a scanning electron micrograph of microspheres prepared with a 50:50 mass ratio of low (12 kDa) and high (100 kDa) molecular weight PLGA (50:50 lactide:glycolide) from BI with preferred process conditions. These microspheres were prepared at low temperature (0°C) without excess methylene chloride in the second emulsion. The final drying step was lyophilization. The microspheres had a protein loading of 1.8% w/w (100% efficiency) and an initial burst of 15% of encapsulated material.

Figure 8 is a graph depicting the in vitro release of MN rgp120 from PLGA microspheres. The microspheres were prepared by using a 50:50 mass ratio of low (18 kDa) and high (100 kDa) molecular weight PLGA (50:50 lactide:glycolide)

supplied by Medisorb Technologies International, L.P. (MTI). The microspheres had a protein loading of 4.4% (w/w) and the final drying step was lyophilization.

Figure 9(a) is a graph depicting far ultraviolet circular dichroism of MN rgp120 released from PLGA microspheres after incubation for 1 hour at 37° C in release medium. The controls are untreated protein in the same medium incubated with (--) or without (—) placebo PLGA microspheres. Microsphere preparations made with 12 kDa (50:50 lactide:glycolide) PLGA from BI (···) and a 50:50 mass ratio of 12 kDa and 100 kDa PLGA (75:25 lactide:glycolide) from BI (-···-) were analyzed. These results indicate that the MN rgp120 released from the microspheres is not altered in its secondary structure.

Figure 9(b) is a graph depicting near ultraviolet circular dichroism of MN rgp120 released from PLGA microspheres after incubation for 1 hour at 37°C in release medium. The controls are untreated protein in the same medium incubated with (--) or without (—) placebo PLGA microspheres. Microsphere preparations made with 12 kDa (50:50) PLGA from BI (···) and a 50:50 mass ratio of 12 kDa and 100 kDa PLGA (75:25 lactide:glycolide) from BI (—···—) were analyzed. These data demonstrate that MN rgp120 released from the microspheres is not altered in its tertiary structure.

Figure 10 is a graph depicting the dose-response of *in vivo* autoboost from PLGA formulations as measured by the antibody titer to MN rgp120. Guinea pigs were dosed with varying amounts of a MN rgp120-PLGA formulation (12 kDa (75:25 lactide:glycolide) PLGA, 2.4% (w/w) MN rgp120). The total antigen dose delivered from the PLGA formulations was 14 (●), 42 (■), or 112 (◆) µg MN rgp120. A control group with a 30 µg MN rgp120 formulated with 60 µg of alum

(Rehydragel™) was also included (O). All animals were given a single injection at the 0 week time point and antibody titers were measured over time. The 14 week time point for the alum control is an estimated titer since this group was boosted at 8 weeks. The antibody titers of alum/gp120 immunized animals always decreased 4-5 weeks after the initial immunization.

Figure 11 is a graph depicting the dose-response of *in vivo* autoboost from PLGA formulations as measured by the antibody titer to the V3 loop of MN rgp120. Guinea pigs were dosed with varying amounts of a gp120-PLGA formulation (12 kDa (75:25 lactide:glycolide) PLGA, 2.4% (w/w) MN rgp120). The total antigen dose delivered from the PLGA formulations was 14 (●), 42 (■), or 112 (◆) µg MN rgp120. A control group with a 30 µg MN rgp120 formulated with 60 µg of alum (Rehydragel™) was also included (O). All animals were given a single injection at the 0 week time point and antibody titers were measured over time. The 14 week time point for the alum control is an estimated titer since this group was boosted at 8 weeks. The antibody titers of alum/gp120 immunized animals always decreased 4-5 weeks after the initial immunization.

Figure 12 is a graph depicting the effect of microencapsulation on the immunogenicity of MN rgp120 and QS21 as measured by antibody titers to MN rgp120. Guinea pigs were immunized at week 0 with MN rgp120 in different formulations: 15 µg of encapsulated and 15 µg of soluble MN rgp120 (O), 30 µg MN rgp120 with 60 µg alum (control, ▲), 30 µg of encapsulated MN rgp120 (●), 30 µg of encapsulated MN rgp120 and 50 µg of soluble QS21 (□), and 25 µg of encapsulated MN rgp120 and 19 µg of encapsulated QS21 in the same microspheres (■). The MN rgp120 encapsulated formulation was produced with a 50:50 mass ratio blend of 12 kDa (75:25 lactide:glycolide) and 100 kDa (75:25

lactide:glycolide) PLGA from Boehringer Ingelheim (BI)(5.0% w/w MN rgp120). The MN rgp120/QS21 encapsulated formulation consisted of both MN rgp120 and QS21 in the same microspheres which were made with a 50:50 mass ratio blend of 12 kDa (75:25 lactide:glycolide) and 100 kDa (75:25 lactide:glycolide) PLGA from BI (2.5% w/w MN rgp120, 1.9% w/w QS21).

Figure 13 is a graph depicting the effect of microencapsulation on the immunogenicity of MN rgp120 and QS21 as measured by antibody titers to the V3 loop of MN rgp120. Guinea pigs were immunized at week 0 with MN rgp120 in different formulations: 15 µg of encapsulated and 15 µg of soluble MN rgp120 (O), 30 µg MN rgp120 with 60 µg alum (control, ▲), 30 µg of encapsulated MN rgp120 (●), 30 µg of encapsulated MN rgp120 and 50 µg of soluble QS21 (□), and 25 µg of encapsulated MN rgp120 and 19 µg of encapsulated QS21 in the same microspheres (■). The MN rgp120 encapsulated formulation was produced with a 50:50 mass ratio blend of 12 kDa (75:25 lactide:glycolide) and 100 kDa (75:25 lactide:glycolide) PLGA from BI (5.0% w/w MN rgp120). The MN rgp120/QS21 encapsulated formulation consisted of both MN rgp120 and QS21 in the same microspheres which were made with a 50:50 mass ratio blend of 12 kDa (75:25 lactide:glycolide) and 100 kDa (75:25 lactide:glycolide) PLGA from BI (2.5% w/w MN rgp120, 1.9% w/w QS21).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A. DEFINITIONS

The terms "polylactide" and "PLGA" as used herein are used interchangeably and are intended to refer to a polymer of lactic acid alone, a polymer of glycolic acid alone, a mixture of such polymers, a copolymer of glycolic acid and lactic acid, a mixture of such copolymers, or a mixture of such polymers and copolymers. A preferred polymer matrix for formation of the microspheres of the instant invention is poly (D-L-lactide-co-glycolide).

The term "antigen" as used herein denotes a compound containing one or more epitopes against which an immune response is desired. Typical antigens will include nucleic acids, proteins, polypeptides, peptides, polysaccharides, and hapten conjugates. Complex mixtures of antigens are also included in this definition, such as whole killed cells, bacteria, or viruses, or fractions thereof.

The term "adjuvant" as used herein denotes a substance that in itself shares no immune epitopes with an antigen of interest, but which stimulates the immune response to the antigen of interest.

The term "therapeutic amount" as used herein denotes an amount that prevents or ameliorates symptoms of a disorder or responsive pathologic physiological condition. In certain embodiments of the present invention, the amount administered is sufficient to raise an immune response which substantially prevents infection or the spread of the infectious agent within the recipient.

The term "polyol" as used herein denotes a hydrocarbon including at least two hydroxyls bonded to carbon atoms.

Polyols can include other functional groups. Examples of polyols useful for practicing the instant invention include sugar alcohols such as mannitol and trehalose, and polyethers.

The term "polyether" as used herein denotes a hydrocarbon containing at least three ether bonds. Polyethers can include other functional groups. Polyethers useful for practicing the invention include polyethylene glycol (PEG).

The term "dry antigen" or "dry adjuvant" as used herein denotes an antigen or adjuvant which has been subjected to a drying procedure such as lyophilization such that at least about 50% of its moisture has been removed.

The term "encapsulation" as used herein denotes a method for formulating an active agent such as an antigen and/or adjuvant into a composition useful for controlled release of the active agent. Examples of encapsulating materials useful in the instant invention include polymers or copolymers of lactic and glycolic acids, or mixtures of such polymers and/or copolymers, commonly referred to as "polylactides" or "PLGA", although any polyester or encapsulating agent may be used. The term "coencapsulation" as used herein refers to the incorporation of two or more active agents, such as adjuvant and antigen, more than one antigen, more than one adjuvant, etc., into the same microsphere.

The term "admixing" as used herein denotes the addition of an excipient to an antigen or adjuvant of interest, such as by mixing of dry reagents or mixing of a dry reagent with a reagent in solution or suspension, or mixing of aqueous formulations of reagents.

The term "excipient" as used herein denotes a non-therapeutic carrier added to a pharmaceutical composition that is pharmaceutically acceptable, i.e., non-toxic to recipients at the dosages and concentrations employed. Suitable excipients and their formulation are described in Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack Publishing Co., Oslo, et al., ed.

The term "organic solvent" as used herein is intended to mean any solvent containing carbon compounds. Exemplary organic solvents include halogenated hydrocarbons, ethers, esters, alcohols and ketones, such as, for example, methylene chloride, ethyl acetate, a mixture of ethyl acetate and benzyl alcohol or acetone, dimethyl sulfoxide, tetrahydrofuran, dimethylformamide, and ethanol.

"Treating" an antigen or adjuvant with an organic solvent as used herein refers to mixing a dry polypeptide with an organic solvent, or making an emulsion of an antigen or adjuvant in an aqueous formulation with an organic solvent, creating an interface between an antigen or adjuvant in an aqueous formulation with an organic solvent, or extracting an antigen or adjuvant from an aqueous formulation with an organic solvent.

"Polypeptide" as used herein refers generally to peptides and proteins having at least about two amino acids.

"Vaccine" as used herein refers to a formulation of an antigen intended to provide a prophylactic or therapeutic response in a host when the host is challenged with the antigen. Exemplary vaccines include vaccines directed against such diseases as hepatitis, polio, herpes, foot and mouth disease, diphtheria, tetanus, pertussis, and malaria, and infection with such agents as cytomegalovirus, HIV, and

Haemophilus sp. Preferred vaccines herein include gp120, vaccinia virus-HIV env recombinant vaccine, and gp160.

"Fluidized bed" as used herein refers generally to a bed of granular particles through which a stream of gas is slowly flowing upward, such that with further increase in gas velocity, the pores and channels enlarge and the particles become more widely separated. Included in this definition are fluidized- or fixed-bed configurations, including but not limited to slurry and trickle-bed reactor systems. Gases used in the fluidized bed are preferably nitrogen, oxygen, and carbon dioxide, although any dry gas which facilitates removal of water and/or other solvents may be used. The methodology for designing a fluidized- or fixed-bed system is widely known in the art, as are examples of fluidized-bed systems useful in practicing the instant invention (see, for example, Perry & Chilton (Chemical Engineers' Handbook, R. H. Perry & C. H. Chilton, Eds., Fifth Edition, pp. 4-20 - 4-40, 5-52 - 5-55, 1973).

The term "harden" as used herein in reference to microspheres refers to the extraction of excess organic solvent from the polymer phase.

B. GENERAL METHODS

In general, microencapsulation of an antigen or adjuvant is performed according to the protocol briefly outlined in Figure 3. In summary, PLGA of the desired ratio of lactide to glycolide (about 100:0 to 0:100, more preferably, about 65:35 to 35:65, most preferably about 50:50 weight percent) and inherent viscosity (generally about 0.1 to 1.2 dL/g, preferably about 0.2 to 0.8 dL/g) is first dissolved in an organic solvent such as methylene chloride, or ethyl acetate with or without benzyl alcohol or acetone to the desired concentration (generally about 0.05 to 1.0 g/mL, preferably

about 0.3 to 0.6 g/mL). A concentrated antigen or adjuvant solution (for example, typically at least 0.1 mg/mL for polypeptides, preferably greater than about 100 mg/mL, depending, for example, on the type of polypeptide and the desired core loading) is then suitably injected (such as with a 25 gauge needle) into the polymer solution while homogenizing at about 15,000 to 25,000 rpm. Dry antigen or adjuvant can be used in place of aqueous antigen or adjuvant. After homogenization (generally about 0.5 to 5 minutes, more preferably for 1 minute), the emulsion is added to the reaction kettle (emulsification bath) or static mixer (not shown) to form a second emulsion. The emulsification bath is typically a polyvinyl alcohol solution, optionally including ethyl acetate. The reaction kettle is mixed at high speed (generally about 1700 to 2500 rpm) to generate small microspheres (about 20 to 100 μm median diameter). The second emulsion is transferred to a hardening bath after a sufficient period of time, generally about 0.5 to 10 minutes, preferably about 1 minute, and allowed to gently mix for a suitable time, generally about 1 to 24 hours, preferably about 1 hour. When hardening is complete, the microspheres are prefiltered (such as with a 150 μm mesh), concentrated and diafiltered. Diafiltering is suitably accomplished in an Amicon stirred cell (2500 mL), preferably with about a 16 or 20 μm filter. The microspheres are washed, typically with about 1 to 100 L, preferably about 15 L of prefiltered water and typically with about 1 to 100 L, more preferably 15 L of 0.1% Tween® 20. The final microspheres are removed from the filter and resuspended in water and filled in vials, preferably at about 500 μL/ vial in 3 cc vials. The microspheres can then be dried. Drying includes such methods as lyophilization, vacuum drying, and fluidized bed drying.

Three other exemplary methods can be employed to produce microspheres. The first method utilizes a solvent evaporation technique. A solid or liquid active agent is

added to an organic solvent containing the polymer. The active agent is then emulsified in the organic solvent. This emulsion is then sprayed onto a surface to create microspheres and the residual organic solvent is removed under vacuum. The second method involves a phase-separation process, often referred to as coacervation. A first emulsion of aqueous or solid active agent dispersed in organic solvent containing the polymer is added to a solution of non-solvent, usually silicone oil. By employing solvents that do not dissolve the polymer (non-solvents) but extract the organic solvent used to dissolve the polymer (e.g. methylene chloride or ethyl acetate), the polymer then precipitates out of solution and will form microspheres if the process occurs while mixing. The third method utilizes a coating technique. A first emulsion comprising the active agent dispersed in a organic solvent with the polymer is processed through an air-suspension coater apparatus resulting in the final microspheres.

When antigen and adjuvant are to be administered from within the same microspheres, a solution containing both antigen and adjuvant or solutions containing antigen and adjuvant separately can be added to the polymer solution. Similarly, soluble antigen and dry adjuvant, dry antigen and soluble adjuvant, or dry antigen and dry adjuvant, can be used. The microspheres of the instant invention are preferably formed by a water-in-oil-in-water emulsion process.

In general, both aqueous formulations and dry polypeptide antigens or adjuvants can be admixed with an excipient to provide a stabilizing effect before treatment with an organic solvent such as methylene chloride. An aqueous formulation of a polypeptide can be a polypeptide in suspension or in solution. Typically an aqueous formulation of the excipient will be added to an aqueous formulation of

the polypeptide, although a dry excipient can be added, and vice-versa. An aqueous formulation of a polypeptide and an excipient can be also dried by lyophilization or other means. Such dried formulations can be reconstituted into aqueous formulations before treatment with an organic solvent.

The excipient used to stabilize a polypeptide antigen of interest will typically be a polyol of a molecular weight less than about 70,000 kD. Examples of polyols that can be used include trehalose (copending U.S.S.N. 08/021,421 filed February 23, 1993), mannitol, and polyethylene glycol (PEG). Typically, the mass ratio of trehalose to polypeptide will be about 1000:1 to 1:1000, preferably about 100:1 to 1:100, more preferably about 1:1 to 1:10, most preferably about 1:3 to 1:4. Typical mass ratios of mannitol to polypeptide will be about 100:1 to 1:100, preferably about 1:1 to 1:10, more preferably about 1:1 to 1:2. Typically, the mass ratio of PEG to polypeptide will be about 100:1 to 1:100, preferably about 1:1 to 1:10. Preferred ratios are chosen on the basis of an excipient concentration which allows maximum solubility of polypeptide with minimum denaturation of the polypeptide.

The formulations of the instant invention can contain a preservative, a buffer or buffers, multiple excipients, such as polyethylene glycol (PEG) in addition to trehalose or mannitol, or a nonionic surfactant such as Tween® surfactant. Non-ionic surfactants include polysorbates, such as polysorbate 20 or 80, and the poloxamers, such as poloxamer 184 or 188, Pluronic® polyols, and other ethylene oxide/propylene oxide block copolymers, etc. Amounts effective to provide a stable, aqueous formulation will be used, usually in the range of from about 0.1%(w/v) to about 30%(w/v).

The pH of the formulations of this invention is generally about 5 to 8, preferably about 6.5 to 7.5.

Suitable buffers to achieve this pH include, for example, phosphate, Tris, citrate, succinate, acetate, or histidine buffers, depending on the pH desired. Preferably, the buffer is in the range of about 2 mM to about 100 mM..

Examples of suitable preservatives for the formulation include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, benzalconium chloride, and benzethonium chloride. Preferred preservatives include about 0.2 to 0.4%(w/v) phenol and about 0.7 to 1%(w/v) benzyl alcohol, although the type of preservative and the concentration range are not critical.

In general, the formulations of the subject invention can contain other components in amounts not detracting from the preparation of stable forms and in amounts suitable for effective, safe pharmaceutical administration. For example, other pharmaceutically acceptable excipients well known to those skilled in the art can form a part of the subject compositions. These include, for example, salts, various bulking agents, additional buffering agents, chelating agents, antioxidants, cosolvents and the like; specific examples of these include tris-(hydroxymethyl)aminomethane salts ("Tris buffer"), and disodium edetate.

Antigens of interest useful in the instant invention include, for example, HIV antigens such as gp120, gp160, gag, pol, Nef, Tat, and Rev; malaria antigens such as CS proteins and sporozoite 2; hepatitis B antigens, including Pre-S1, Pre-S2, HBcAg, HBsAg, and HBeAg; influenza antigens such as HA, NP, and NA; hepatitis A surface antigens; Herpes virus antigens such as EBV gp340, EBV gp85, HSV gB, HSV gD, HSV gH, and HSV early protein product; cytomegalovirus antigens such as gB, gH, and IE protein gP72; respiratory syncytial virus antigens such as F protein, G protein, and N protein. Polypeptides or protein fragments defining immune epitopes,

and amino acid variants of proteins, polypeptides, or peptides, can be used in place of full length proteins. Polypeptides and peptides can also be conjugated to haptens.

Multivalent vaccines can be formulated with mixtures of antigens, either first mixed together and then encapsulated, or first encapsulated and then mixed together in a formulation for administration to a patient. Such mixtures can consist of two to upwards of about 100 antigens. The antigens can represent antigenic determinants from the same organism, such as gp120 polypeptides isolated from geographically different strains of HIV, or from different organisms, such as diphtheria-pertussis-tetanus vaccine.

Exemplary adjuvants of interest include saponins such as QS21, muramyl dipeptide, muramyl tripeptide, and compounds having a muramyl peptide core, mycobacterial extracts, aluminum hydroxide, proteins such as gamma interferon and tumor necrosis factor, phosphatidyl choline, squalene, Pluronic® polyols, and Freund's adjuvant (a mineral oil emulsion) (see the Background of this application for specific references). Although antigen is desirably administered with an adjuvant, in situations where the initial inoculation is delivered with an adjuvant, boosts with antigen may not require adjuvant. PLGA or other polymers can also serve as adjuvants.

Typically, an antigen of interest will be formulated in PLGA microspheres to provide a desired period of time between the first and second bursts of antigen and to provide a desired amount of antigen in each burst. The amount of antigen in the initial burst can be augmented by soluble antigen in the formulation. Preferably, an adjuvant is microencapsulated, although soluble adjuvant can also be administered to the patient.

The microspheres, soluble antigen, and/or adjuvant are placed into pharmaceutically acceptable, sterile, isotonic formulations together with any required cofactors, and optionally are administered by standard means well known in the field. Microsphere formulations are typically stored as a dry powder.

The amount of antigen delivered to the patient to be used in therapy will be formulated and dosages established in a fashion consistent with good medical practice taking into account the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Similarly, the dose of the vaccine administered will be dependent upon the properties of the antigen employed, e.g. its binding activity and in vivo plasma half-life, the concentration of the antigen in the formulation, the administration route, the site and rate of dosage, the clinical tolerance of the patient involved, the pathological condition afflicting the patient and the like, as is well within the skill of the physician. Generally, doses of from about 0.1 to 1000 μg per patient per administration are preferred. Different dosages can be utilized during a series of sequential inoculations; the practitioner can administer an initial inoculation and then boost with relatively smaller doses of vaccine.

It is envisioned that injections (intramuscular or subcutaneous) will be the primary route for therapeutic administration of the vaccines of this invention, although intravenous delivery, or delivery through catheter or other surgical tubing is also used. Alternative routes include suspensions, tablets, capsules and the like for oral administration, commercially available nebulizers for liquid formulations, and inhalation of lyophilized or aerosolized microcapsules, and suppositories for rectal or vaginal

administration. Liquid formulations can be utilized after reconstitution from powder formulations.

The adequacy of the vaccination parameters chosen, e.g. dose, schedule, adjuvant choice and the like, can be determined by taking aliquots of serum from the patient and assaying antibody titers during the course of the immunization program. Alternatively, the presence of T cells or other cells of the immune system can be monitored by conventional methods. In addition, the clinical condition of the patient can be monitored for the desired effect, e.g. anti-infective effect. If inadequate vaccination is achieved then the patient can be boosted with further vaccinations and the vaccination parameters can be modified in a fashion expected to potentiate the immune response, e.g. increase the amount of antigen and/or adjuvant, complex the antigen with a carrier or conjugate it to an immunogenic protein, or vary the route of administration.

The microspheres of the instant invention are designed to release their contents in a triphasic manner consisting of an initial burst, a slow release, and a second burst. The degradation rate for the microspheres of the invention is determined in part by the ratio of lactide to glycolide in the polymer and the molecular weight of the polymer. Polymers of different molecular weights (or inherent viscosities) can be mixed to yield a desired degradation profile. Furthermore, populations of microspheres designed to have the second burst occur at different times can be mixed together to provide multiple challenges with the antigen and/or adjuvant at desired intervals. Similarly, mixtures of antigens and/or adjuvants can be provided either together in the same microspheres or as mixtures of microspheres to provide multivalent or combination vaccines. Thus, for example, rather than receive three immunizations with traditional DTP (diphtheria, tetanus, and pertussis)

vaccine at 2, 4, and 6 months, a single microencapsulated vaccine can be provided with microspheres that provide second bursts at 2, 4, and 6 months.

The microspheres of the instant invention can be prepared in any desired size, ranging from about 0.1 to upwards of about 100 μm in diameter, by varying process parameters such as stir speed, volume of solvent used in the second emulsion step, temperature, concentration of PLGA, and inherent viscosity of the PLGA polymers. The relationship of these parameters is discussed in detail below. The microspheres used for the gp120 vaccine of the instant invention are of a median diameter of generally about 20 to 100 μm, preferably about 20 to 50 μm, more preferably about 30 μm.

The HIV vaccine of the instant invention will typically comprise three populations of PLGA microspheres: microspheres containing 1-5% w/w gp120, generated with a 50:50 mass ratio of PLGA polymers having inherent viscosities of 0.2 and 0.75 dL/g, wherein the ratio of lactide to glycolide is 50:50 (preparation 1); microspheres containing 1-8% w/w QS21, generated with a 50:50 mass ratio of PLGA polymers having inherent viscosities of 0.2 and 0.75 dL/g, wherein the ratio of lactide to glycolide is 50:50 (preparation 2); and microspheres containing 1-5% gp120, generated with PLGA polymers having inherent viscosities of 0.7 to 1.2 dL/g, wherein the ratio of lactide to glycolide is 50:50 (preparation 3). Soluble gp120 will also be provided in the vaccine at a concentration of about 300 to 1000 μg/dose, more preferably, 300 to 600 μg/dose. Soluble QS21 will also be provided in the vaccine at a concentration of about 50 to 200 μg/dose, more preferably, 50 to 100 μg/dose. This vaccine formulation will result in an initial exposure by the patient to about 300 to 600 μg gp120 and 50 to 100 μg QS21 at the time of parenteral inoculation, a slow release of less than

50 µg gp120 and less than 10 µg QS21 over about 120 to 180 days, a challenge ("autoboost") with about 300 to 600 µg gp120 and 50 to 100 µg QS21 at about 30 to 60 days resulting from the second burst from microsphere preparations 1 and 2; and another autoboost with about 300 to 600 µg gp120 at about 30 to 60 days resulting from the second burst of microsphere preparation 3.

Further details of the invention can be found in the following examples, which further define the scope of the invention. All references cited herein are expressly incorporated by reference in their entirety.

EXAMPLES

I. MATERIALS AND METHODS

A. PLGA

Poly(D-L-lactide-co-glycolide) (PLGA) was purchased from both Boehringer Ingelheim (BI) and Medisorb Technologies International L.P. (MTI). Various molecular weights and lactide to glycolide ratios of PLGA were used to assess the effect of these parameters on the microsphere properties (Table 1). PLGA at 12 kDa and 100 kDa were obtained from BI, and PLGA at 18 kDa and 100 kDa were obtained from MTI. The polymer compositions were either 50:50 or 75:25 lactide:glycolide. The 10% polyvinyl alcohol solution (PVA Airvol 205, Air Products) was prepared by dissolving solid PVA in warm water (about 80° C). The final PVA solution was filtered with 0.22 µm Millipak filters from Millipore. Methylene chloride (technical grade) was purchased from Baxter S/P.

Table 1: Polylactide-coglycolide (PLGA) Used for Microsphere Formulations

Vendor	Inherent Viscosity [a] (dL/g)	Molecular Weight [b] (kDa)	Lactide:Glycolide [c]	Lot #
BI	0.21	12	48:52	15068
	N.A.	12	75:25*	15056
	0.76	100	48:52	05076
	N.A.	100	75:25*	15045
MTI	0.24	18	50:50*	622-84
	0.21	24	72:27	622-92A
	0.75	95	51:49	S21268174
	0.62	100*	74:26	S2101SE168

[a] Inherent viscosity of polymers dissolved in chloroform. N.A. denotes not available.

[b] Molecular weights were determined by using gel permeation chromatography with polystyrene standards. Polymers dissolved and analyzed in methylene chloride at room temperature. Molecular weight shown is a weight average value. Values for BI polymers are approximate since specifications were not included with the product*.

[c] Lactide to glycolide molar ratio in PLGA as measured by vendor is usually within 3% of specifications. Specifications are either 50:50 or 75:25 lactide:glycolide for these polymers.

* Estimated values based on specifications for polymer type Actual values not available.

B. Preparation of rgp120

MN rgp120 (Lot# Y16531/G90557) was supplied in bulk at 2.3 mg/mL protein in 20 mM Tris, 0.120 M NaCl, pH 7.4 from Genentech, Inc. It was concentrated with a Amicon stirred cell concentrator using a YM 30,000 MW cutoff membrane at 4° C to a final concentration of 154 mg/mL and stored at 2 to 8°C.

C. Preparation of QS21

Lyophilized QS21 (about 80% pure, Lot# D1949) was supplied from Cambridge Biotech (Cambridge, MA). QS21 was prepared at 200 mg/mL by dissolving the lyophilized QS21 powder in 50% ethanol/water. QS21 was also dissolved in 50% ethanol with 20% Tween® 20 in an attempt to increase the

encapsulation efficiency and release rate. The QS21 solutions were prepared and used on the same day as the encapsulation.

D. Microencapsulation of gp120

The production of rgp120 microspheres was performed by a double emulsion water-in-oil-in-water (WOW) as discussed above in general terms. More specifically, the PLGA concentrations in methylene chloride were 0.3 or 0.6 g/mL, and the first emulsion was homogenized at 15,000 rpm and 0 to 1° C in a water bath. After 1 minute of homogenization, the first emulsion (10 mL) was added to 900 mL of 10% PVA solution containing 1.5% methylene chloride and emulsified at high speed (800 to 2500 rpm) for 1 minute in the reaction kettle (2 to 8° C). To improve the encapsulation efficiency, the second emulsion was also performed with 10% PVA that did not contain methylene chloride and the temperature of the second emulsion was maintained at 0 to 3° C. To achieve the reduced temperature, the ethylene glycol in the cooling jacket of the reaction kettle was kept at -15° C. The second emulsion was then transferred to the hardening bath containing 12 liters of prefiltered water (MilliQ water system, Millipore Corp.) at 2 to 8° C. The microspheres were allowed to harden for 1 hour. The hardened microspheres were concentrated to about 1.5 L and diafiltered against 15 L of prefiltered water followed by 15 L of 0.1% Tween® 20. The Amicon stirred cell (2.5 L) was operated with different filter systems depending upon the desired particle size. After washing, the microspheres were concentrated to dryness. The concentrated microspheres were removed from the filter by using a cell scraper and resuspended in prefiltered water to about 0.3 gm/mL.

Three different drying methods were used to dry the microspheres: lyophilization, vacuum drying, and fluidized

bed drying by using the system shown in Figure 4 or a 5 mL Amicon stirred cell. A suspension of the final microspheres was added to the airlift drier (Figure 4) or a stirred cell and the residual liquid was removed by applying a slight (about 2 psi) nitrogen pressure to the column (nitrogen flow downward). After the residual liquid was removed, the nitrogen flow was directed upward through the airlift drier or Amicon stirred cell to suspend the microspheres. The nitrogen line was connected to a prefilter (0.22 μm) for the stirred cell and a desiccating column with prefilters for the airlift drier. A water bath was connected to the jacket of the airlift drier to maintain the system at 5° C. The Amicon stirred cell drying was performed in a 2 to 8° C cold room. A few batches were also vacuum dried at higher temperatures (10° C or 15° C) to speed up the drying process without increasing the initial burst.

E. Encapsulation of QS21

QS21 was dissolved in 50% ethanol with or without Tween® 20 as described above. As with the rgp120 solutions, the QS21 solution was injected into the polymer phase. For the microsphere preparations containing both rgp120 and QS21, the rgp120 solution was injected into the polymer phase after the QS21 solution to reduce the potential interaction between rgp120 and the ethanol in the QS21 solution. The microencapsulation of QS21 was performed with conditions similar to those described above for rgp120.

F. Microsphere Size Analysis

The apparent diameters of microspheres in water were measured by using a Brinkmann Particle Size Analyzer Model 2010 (Lens A, 1 to 150 μm range).

G. Scanning Electron Microscopy of Microspheres

The size and appearance of the dried microspheres were analyzed using Phillips Model 525M SEM. The microspheres were coated to a thickness of 10 nm with gold-palladium using HummerXP, Anatech.

H. Microsphere Loading and Release Characteristics for MN rgp120

The protein content of the MN rgp120-PLGA microspheres was determined as follows. Dried microspheres were added (10 to 20 mg) to 1 mL of 1 N NaOH and allowed to dissolve by shaking at room temperature for 2 to 16 hours. Standards of rgp120 were prepared by adding 5 N NaOH to the stock solution of MN rgp120 (1.5 mg/mL) to yield a 1 N NaOH solution. In 1 N NaOH, tyrosine is deprotonated resulting in a significant shift in the absorbance maximum and, thus, protein dissolved in 1 N NaOH will have a different absorbance spectrum than native protein in buffer at neutral pH. Standard solutions containing different concentrations of MN rgp120 in 1 N NaOH were used to determine the shifted absorbance maxima of the protein and the extinction coefficient at this wavelength. The extinction coefficient for MN rgp120 in 1 N NaOH was 1.39 cm-1(mg/mL)-1 at 284 nm.

The amount of protein released from the microspheres was determined by the Pierce Chemical Co. BCA Protein Assay. Both lyophilized and "wet" microspheres were analyzed. "Wet" microspheres were defined as microspheres that were removed from the diafiltration cell and suspended in release medium without additional processing. The amount of protein released was then used to calculate the percent of MN rgp120 released (percent of total) from the microspheres based on the mass of microspheres in the release device, the protein loading of the microspheres, and the volume of the release

medium (20 mg of microspheres in 300 µL of 10 mM Hepes, 100 mM NaCl, 0.02% (w/w) Tween® 20, 0.02% NaN3, pH 7.4).

I. Characterization of rgp120 Release from Microspheres

MN rgp120 released from microspheres after 1 hr of incubation in the release medium was analyzed by circular dichroism, analytical HPLC assays such as reverse phase, size exclusion, CD4 binding, and clipping, and ELISAs for epitopes to the total protein (Total MN) and the V3 loop. The aggregation of rgp120 was quantitated by a SEC HPLC. A TSK G3000 SW XL (0.78 X 30 cm) column, equilibrated in 0.4M KPO_4, pH 7.0, was used at a flow rate of 0.5 mL/min. Competitive binding assays (native labeled gp120 versus sample) were performed to assess the binding of CD4-IgG to gp120 released from the microspheres. For the microsphere preparations that were administered to guinea pigs, endotoxin assays were also performed.

J. Determination of QS21 Microsphere Loading

The amount of QS21 encapsulated in the PLGA microspheres was determined by dissolving the microspheres in 1 N NaOH at room temperature overnight. The completely dissolved solutions were neutralized with 6 N HCl. The samples were then injected onto a SEC column, TSK G3000SW XL (0.78 x 30 cm), equilibrated in 0.4 M KPO_4, pH 7.0. The column running conditions were the same as those used for the SEC analysis of rgp120. Since QS21 degrades in 1 N NaOH, the chromatographs from SEC analysis contained several peaks. To quantify the total amount of QS21, the peak areas corresponding to QS21 and its degradation products were used in the determination of the core loading. As standards, known amounts of QS21 were added to placebo microspheres and then treated with 1 N NaOH. SEC analysis was performed on

the standards and the peak areas from the standards were used to calculate the amount of QS21 in each sample.

K. Determination of QS21 Release from Microspheres

QS21 released from microspheres was quantitated by a 5 μm YMC C4 (0.46 x 25 cm) RP-HPLC with 1 mL/min flow rate and detection at 214 nm. A linear gradient was run in 15 minutes from 25 to 75% of solution B (Solution A: 0.1% TFA in water; Solution B: 0.1% TFA in 90% acetonitrile). QS21 controls were also run. In RP-HPLC analysis, the rgp120 peak elutes before the QS21 peak and, therefore, this method provides simultaneous quantitation of QS21 and rgp120 released from the microspheres.

L. Guinea Pig Studies

Guinea pigs (Hartley strain) were supplied by Charles River Laboratories. The animals were immunized by subcutaneous administration (200 μL) of the formulations. After immunization, the animals were bled by cardiac puncture at weeks 4, 6, 8, 14, and 20. The animal sera from each group (five animals per group in each experiment) at a given time point were pooled and analyzed for antibodies to MN rgp120 or the V3 loop of MN rgp120. The antibody assays were performed by ELISA methods by using either MN rgp120 or the linear peptide of the V3 loop of MN rgp120 as the coat protein on the microtiter plates. The antibody titers were determined by serial dilution of the samples. The endpoint titer value was defined as the dilution factor that resulted in a value two fold over the background and was determined by interpolation of the serial dilution values.

In separate studies, guinea pigs were immunized subcutaneously (200 μL) at 0, 1, and 2 months with different formulations. After 70 days, the animals were bled by

cardiac puncture. The sera from each group were pooled and analyzed for ability to neutralize both the MN and ALA-1 strains of HIV-1. The virus strains were prepared from infected H9 cells. An inoculation titer of virus sufficient to completely kill cells in 7 days was incubated with serial dilutions (3 fold) of the test sera, and then added to MT4 T-lymphoid cells in 10% FCS/RPMI-1640 cell culture media. The cultures were incubated at 37° C for 7 days and the cell viability was then quantitated by the MTT dye assay with optical density measurements at 570-650 nm (Mosmann, J. Immunol. Methods 65:55-63, [1983]). The endpoint titer values for the virus neutralization were defined as the dilution factor that resulted in an optical density reading two fold over the background of unprotected (killed) cells. These titers were typically twice those calculated at 50% protection.

M. Clipping Assays

To determine whether proteolysis of the V3 loop of MN rgp120 occurred, the protein was denatured in 0.1% sodium dodecyl sulfate/20 mM dithiothreitol and analyzed by size exclusion chromatography. Clipped MN rgp120 elutes as two species. The fraction of clipped protein is calculated from the peak area for intact protein.

II. Results

A. Process Modifications for Improved Loading, Efficiency, and Initial Burst

These and other encapsulation studies revealed an empirical correlation between encapsulation efficiency (E), which is the ratio of experimental and theoretical protein loading, and the composition of the first phase:

$$E \propto \frac{\mu_p}{\left(V_a / V_o\right) T V_{MeCl_2}} \qquad (1)$$

where μp is the viscosity of the polymer phase, V_a/V_o is the volume ratio of aqueous to organic solutions in the first emulsion, $VMeCl_2$ is the volume of methylene chloride in the second emulsion prior to polymer addition, and T is the temperature of the first and second emulsions. As indicated in previous studies, increasing the polymer concentration in the first phase from 0.1 to 0.3 g PLGA/mL methylene chloride yielded a two fold increase in encapsulation efficiency (to about 40%).

To further increase the encapsulation efficiency and loading, the effect of temperature on gp120 encapsulation was studied. These studies were performed with a 50:50 mass ratio of 12 kDa and 100 kDa PLGA (75:25 lactide:glycolide, Boehringer Ingelheim) at a polymer concentration of 0.3 g/mL and an aqueous to organic volume ratio of 0.1 mL/m. At these conditions, the encapsulation efficiency was 22% for room temperature operation and 55% for low temperature operation (0° C, Table 2). These results indicated that a reduction in operating temperature dramatically increased the process efficiency. The protein loading was also increased from 1.2 to 2.8% (w/w) by operation at the lower temperature. The reduced temperature of the first emulsion increases the viscosity of the polymer solution and reduces the propensity of the aqueous droplets to coalesce. The second emulsion can also be stabilized by the reduced temperature because the embryonic microspheres are less sensitive to shear forces. In both cases, the lower temperature should further stabilize the protein solution by freezing it into small droplets which are created during homogenization.

Table 2: Effect of Temperature and Excess Methylene Chloride on the Encapsulation Efficiency, Loading, and Initial Burst[a]

Process Conditions	Protein Loading (% w/w)	E (%)	Initial Burst (1 hr)[b] wet	lyo	vac
12/100 kDa (75:25) BI [c]					
with $MeCl_2$ [d], RT [e]	1.2	22	21	75	68
with $MeCl_2$, 0 °C	2.8	55	23	42	53
No $MeCl_2$, 0 °C	4.9	96	10	32	ND[f]
18/100 kDa (50:50) MTI [c]					
with $MeCl_2$ [d], RT [e]	0.6	11	23	64	52
No $MeCl_2$, 0 °C	4.4	86	16	33	ND[f]

a Microspheres were prepared as described in the text.

b The microspheres were analyzed for release of gp120 either after production while still wet or after drying by lyophilization (lyo), or vacuum (vac, 5° C for 1 week).

c A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

d The second emulsion (reaction kettle with 10% PVA) was either saturated with methylene chloride 1.5% or did not contain methylene chloride prior to the addition of the first emulsion.

e RT denotes room temperature (about 25° C). Temperature corresponds to the operating temperature of both the first and second emulsions.

f ND denotes not determined

The effect of methylene chloride saturation in the second emulsion was also investigated. As the amount of methylene chloride in the second emulsion prior to polymer addition is reduced, the encapsulation efficiency should increase (Equation 1). The same conditions that were used in the temperature study were applied to this analysis. The encapsulation was performed at 0° C with the second emulsion either saturated with methylene chloride (1.5%) or without methylene chloride. Removal of excess methylene chloride from the second emulsion increased the encapsulation efficiency from 55% to 96% (protein loading: 2.8 to 4.9% (w/w), see Table 2). These results indicate that the second emulsion does not require methylene chloride prior to polymer addition. The removal of excess methylene chloride from the second emulsion causes more rapid extraction of the solvent

from the microspheres and, thereby, allows the microspheres to harden more quickly, thereby entrapping a larger amount of protein.

To further confirm these observations, a different polymer system was used at the same conditions. This polymer blend, 50:50 mass ratio of 18 kDa and 100 kDa PLGA (75:25 lactide:glycolide, MTI), was less viscous in methylene chloride than the previous blend at the same concentration of 0.3 g/mL. Therefore, the encapsulation efficiency at room temperature with methylene chloride in the second emulsion was only 11%. By decreasing the operation temperature to 0° C and removing the methylene chloride from the second emulsion, the encapsulation efficiency was increased to 86%. These changes also increased the protein loading from 0.6 to 4.4% (w/w) (Table 2). In addition, the initial burst from the wet (analyzed immediately after the production), lyophilized and vacuum dried microspheres was significantly decreased by reducing the operating temperature and removing the excess methylene chloride from the second emulsion (Table 2). The initial burst at low protein loading (less than 10% w/w) can be empirically correlated to the inverse of the encapsulation efficiency as defined in Equation 1. By decreasing the process temperature and removing excess solvent, the process efficiency, protein loading and initial burst were improved.

Equation 1 also indicates that the encapsulation efficiency is increased by increasing the viscosity of the polymer phase and decreasing the ratio of aqueous to organic volumes in the first phase. The viscosity of the first phase increases with increasing polymer concentration (g PLGA/mL methylene chloride) and molecular weight. To investigate the relationship between polymer molecular weight and the encapsulation efficiency, microspheres were produced by using several polymers with the same process conditions (V_a/V_o=0.1,

0.3 g/mL PLGA, reduced temperature, no excess methylene chloride). The initial studies were performed to evaluate differences in viscosity of the polymers from two separate vendors. A blend of an equal mass ratio of high and low molecular weight polymers from each supplier, MTI and BI, was used for microencapsulation. The microspheres made from 12 kDa and 100 kDa (75:25 lactide:glycolide) PLGA from BI yielded a protein loading of 5.0% (w/w) and an encapsulation efficiency of 98%. The microspheres produced with 18 kDa and 100 kDa (50:50 lactide:glycolide) PLGA from MTI yielded a slightly lower protein loading (4.4% w/w) and a reduced encapsulation efficiency (86%, Table 3). The initial burst from both preparations after lyophilization was equivalent (32 to 37%). These results indicated that there were not significant differences between the polymers from different vendors at these conditions.



Table 3: Correlation Between Polymer Properties and Encapsulation Efficiency, Loading, and Initial Burst[a]

Polymer (lactide/glycolide)	Protein Loading (% w/w)	E (%)	Initial Burst (1 hr)[b] wet	lyo	vac
12 kDa (50:50) BI	3.0	58	43	70	67
12 kDa (75:25) BI	2.4	47	36	61	57
12/100 kDa (75:25) BI [c]	4.9	96	10	32	ND[d]
12/100 kDa (75:25) BI [c]	5.0	98	8	37	71
18 kDa (50:50) MTI	2.4	92	6	49	ND
18 kDa (75:25) MTI	2.5	96	6	36	24
100 kDa (75:25) MTI	5.1	100	2	ND	18
18/100 kDa (50:50) MTI [c]	4.4	86	16	33	ND

a Microspheres were prepared as described in the text

b The microspheres were analyzed for release of gp120 either after production while still wet or after drying by lyophilization (lyo), or vacuum (vac, 5° C for 1 week).

c A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres

d ND denotes not determined.

In addition, the molecular weight and composition of the PLGA was investigated for its effect on encapsulation efficiency. Low molecular weight polymers from both vendors were analyzed. Microspheres produced from 12 kDa (75:25 lactide:glycolide) or 12 kDa (50:50 lactide:glycolide) PLGA from BI were only slightly different in their final characteristics. Both preparations of microspheres were produced under the same conditions (V_a/V_o=0.1, 0.3 g/mL PLGA, reduced temperature, no excess methylene chloride). By using the 12 kDa (75:25 lactide:glycolide) PLGA, an encapsulation efficiency of 47% was achieved and the microspheres had a protein loading of 2.4% w/w. These microspheres also had a moderate initial burst for the material which had not been dried (36% for wet microspheres, Table 3). By using the 12

kDa (50:50 lactide:glycolide) PLGA, an encapsulation efficiency of 58% was obtained and the protein loading was 3.0% w/w. Although the 12 kDa (50:50 lactide:glycolide) PLGA had a slightly better loading, the initial burst was greater (43%) and, therefore, the loading of the microspheres after the initial burst was nearly equivalent (1.5% w/w for 75:25 lactide:glycolide and 1.7% w/w for 50:50 lactide:glycolide). In both cases, the encapsulation efficiency was significantly lower than the equal mass ratio blend of high and low molecular weight PLGA (Table 3).

To increase encapsulation efficiency, the viscosity of the low molecular weight polymer solutions was increased by increasing the polymer concentration to 0.6 g/mL. Increasing the polymer concentration without increasing the amount of gp120 added to the first phase results in a reduction of the theoretical protein loading. This relationship is described by a simple mass balance on the components in the system:

$$L = \frac{1}{\left\{\frac{[PLGA]}{V_a / V_o\,[gp120]} + 1\right\}} = \frac{\text{Total gp120}}{(\text{Total gp120} + \text{PLGA})} \qquad (2)$$

where L is the theoretical loading (gp120 mass fraction of total), [PLGA] is the PLGA concentration (g PLGA/mL methylene chloride) in the first phase, and [gp120] is the gp120 concentration (g/mL) in the aqueous solution injected into the first phase. Therefore, under these conditions, the increase in PLGA concentration from 0.3 to 0.6 g/mL decreased the theoretical loading by about one half to 2.6%. These experiments were performed with the low molecular weight polymers (18 kDa) obtained from MTI. For both the 50:50 and 75:25 lactide:glycolide 18 kDa PLGA, the encapsulation efficiency was dramatically improved (92 to 96%) and the protein loading was 2.4 to 2.5% w/w (Table 3). In addition, the initial bursts from both preparations were nearly

equivalent and the lyophilized material had a moderate initial burst (Table 3). Therefore, a high encapsulation efficiency (greater than 90%) was achieved with the low molecular weight PLGA when the PLGA concentration in the first phase was increased to 0.6 g/mL. These results further validate Equation 1 since the increased viscosity of the first phase was achieved by increasing the PLGA concentration.

Unlike the low molecular weight PLGA, the high molecular weight PLGA (100 kDa) was very viscous in methylene chloride at 0.3 g/mL. Microencapsulation of gp120 in 100 kDa (75:25 lactide:glycolide) PLGA from MTI at 0.3 g/mL (V_a/V_o=0.1, reduced temperature, no excess methylene chloride) resulted in 100% encapsulation of the protein and a protein loading of 5.1% w/w. These microspheres also had a very low initial burst even after drying (Table 3). Because the high molecular weight PLGA is much more viscous than the low molecular weight PLGA, a blend of both polymers should provide sufficient viscosity to allow encapsulation at 0.3 g PLGA/mL methylene chloride and decrease the large initial burst obtained when using the low molecular weight PLGA. To test this hypothesis, equal mass ratios of high and low molecular weight PLGA from both vendors were used to microencapsulate gp120 as described above. These preparations were produced with a high encapsulation efficiency (greater than 85%) and both lyophilized preparations had lower initial bursts than the microspheres made with only low molecular weight PLGA.

Increasing viscosity of the first emulsion through changes in the polymer (concentration or molecular weight) or reductions in temperature results in an increase in the size of the final microspheres. In general, the correlation between microsphere diameter, D, and process parameters is empirically described by:

$$D \propto \frac{\mu_p}{\omega_r T V_{MeCl_2}} \qquad (3)$$

where ω_r is the stir speed in the second emulsion (rpm).

When the temperature was reduced to 0° C and excess methylene chloride was added to the second emulsion, the microsphere diameter did not change for the preparations that were made with a blend of the low and high molecular weight polymers (Table 4). However, if the temperature of the emulsions was reduced and the excess methylene chloride was removed, the diameter of the microspheres produced with the same conditions was increased by a factor of two. Increasing the PLGA concentration from 0.3 to 0.6 g/mL also resulted in a doubling of the microsphere diameter, assuming that the low molecular weight PLGA from BI or MTI yields about the same diameter under the same process conditions (Table 4). The high molecular weight PLGA (100 kDa, MTI) was more viscous in the methylene chloride phase and the diameter of the microspheres produced with this polymer was three times greater than the low molecular weight PLGA, even though the impeller speed in the second emulsion was increased slightly. Reducing the impeller speed by 1000 rpm produced microspheres that were 50% larger for the low molecular weight PLGA (18 kDa, MTI). The equal mass ratio blends of low and high molecular weight PLGA were about twice the diameter of microspheres that were made from the low molecular weight PLGA with the same process conditions. Because increases in the viscosity of the first phase, reductions in temperature, and removal of excess methylene chloride are necessary to improve the encapsulation efficiency, the impeller speed in the second emulsion is preferably at its maximum (2500 rpm) to produce small microspheres (less than 20 μm).

Table 4: Effect of Initial Phase Viscosity on Microsphere Size[a]

Polymer (lactide/glycolide)	[PLGA] [b] (g/mL)	T [c] (° C)	V_{MeCl2} [d] (mL)	ω_r [e] (rpm)	Median Diameter [f] (μm)
12 kDa (50:50) BI	0.3	0	0	2000	10
12 kDa (75:25) BI	0.3	0	0	2000	12
12/100 kDa (75:25) BI [g]	0.3	0	0	2200	22
12/100 kDa (75:25) BI [g]	0.3	0	0	2500	22
12/100 kDa (75:25) BI [g]	0.3	0	13.5	2000	9
12/100 kDa (75:25) BI [g]	0.3	RT	13.5	2000	9
18 kDa (50:50) MTI	0.6	0	0	1200	34
18 kDa (75:25) MTI	0.6	0	0	2200	22
100 kDa (75:25) MTI	0.3	0	0	2500	31
18/100 kDa (50:50) MTI [g]	0.3	0	0	2000	21
18/100 kDa (50:50) MTI [g]	0.3	RT	13.5	2000	6

a Microspheres were prepared as described in the text.
b Concentration of PLGA dissolved in methylene chloride in the first phase.
c Temperature of both emulsions during production (RT denotes room temperature, about 25° C).
d Volume of methylene chloride in the second emulsion prior to addition of the first emulsion. 13.5 mL of methylene chloride in 900 mL 10% PVA results in saturation.
e Impeller speed in the second emulsion.
f Median diameter (volume basis) measured by photointeruption method (Materials and Methods).
g A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

B. Effect of Drying on Initial Burst and Quality of the Microspheres

To investigate the correlations among the initial burst, polymer, and drying technique, drying experiments were performed on several microsphere preparations. The drying techniques used in these studies were lyophilization, vacuum drying, and nitrogen drying. The amount of initial protein released (1 hour incubation) from microspheres dried with

each of these techniques was compared to the initial burst from microspheres that were analyzed immediately after production (wet). The microspheres analyzed without drying always had an initial burst that was less than microspheres dried by either drying method. When hydrated, the microspheres will hydrolyze and release the encapsulated protein and, thus, excess moisture is preferably removed at the end of the microsphere process. Prior to complete drying, the microspheres are fully hydrated, resulting in hydrolysis of the PLGA with subsequent release of protein at or near the surface. The formation of microspheres in the second emulsion will affect the amount of protein at or near the surface. Larger microspheres produced in the second emulsion would have a smaller initial burst since the surface area to volume ratio is decreased. The first technique used to assess these possible effects on degradation of the microspheres during drying was vacuum drying. Unfortunately, when vacuum dried microspheres are fully hydrated for several days (dried at 5° C for 7 days) the protein can be released during the drying process. Therefore, the drying time is preferably minimized to reduce the initial burst.

One method used to reduce the microsphere drying time was lyophilization, which usually requires only one to two days. Lyophilization or vacuum drying of the low molecular weight PLGA formulations resulted in 1.5 to 8-fold increase in the initial burst (Tables 2 and 3). Aqueous protein droplets encapsulated at or near the surface of the microspheres probably cause the initial burst from these microspheres. If the viscosity of the first emulsion is increased, the aqueous droplets formed during homogenization are less likely to coalesce. Thus, small droplets at or near the surface will release less total protein for microspheres containing the same total aqueous volume. To increase the viscosity of the first emulsion, the PLGA concentration in the methylene chloride can be raised. By increasing the PLGA

(12 kDa) concentration from 0.3 to 0.6 g/mL, the initial burst from lyophilized or vacuum dried microspheres was reduced from greater than 50% to 30 to 50%. Initial microspheres produced at 0.3 g/mL 12 kDa (50:50 lactide:glycolide) PLGA in the first emulsion were also cracked and broken after lyophilization (Figure 5). During lyophilization, the microspheres are frozen and the excess water remcved by sublimation. The formation of ice crystals within the microspheres can contribute to cracking or complete fracture of the microspheres. The stability of the aqueous droplets can be increased by increasing the viscosity of the first emulsion through reductions in temperature and by removing the excess methylene chloride from the second emulsion, causing a more rapid formation of microspheres. When the process conditions were modified to include both these changes, the microspheres were not broken or cracked after lyophilization or vacuum drying (Figure 6). However, both the vacuum dried and lyophilized microspheres shown in Figure 6 had a large initial burst (greater than 65%). The large initial burst is likely the result of the instability of the first emulsion encapsulated within the microspheres. More aqueous droplets can accumulate at the surface if the polymer is warmed above 2 to 8° C and, thus, provide the large initial burst that was observed in the intact microspheres.

In contrast, lyophilization did not cause cracking or breakage of microspheres produced with either an equal mass ratio blend of high and low molecular weight PLGA (Figure 7) or high molecular weight PLGA alone when produced at low temperature without excess methylene chloride in the second emulsion. These microsphere preparations also did not have a large initial burst (less than 30%, Table 5). In addition, microspheres produced with the high molecular weight PLGA had a much lower initial burst after lyophilization or vacuum drying (Tables 3 and 5). Both the equal mass ratio blend of

high and low molecular weight polymer and the high molecular weight polymer preparations did not reveal a correlation between protein loading and initial burst for loadings ranging from 1.8 to 3.9% w/w. However, at very low protein loading (0.5% w/w), microspheres produced with the same conditions had a greatly reduced initial burst. Because the initial burst is controlled by the diffusion of protein out of the microspheres, the rate of release (initial burst) will be dependent upon the concentration difference between the bulk solution and the hydrated, accessible protein (surface protein). The amount of protein at the surface will also be reduced since the protein concentration in the aqueous droplets is reduced. In general, the initial release of gp120 from the microspheres is dependent upon the polymer molecular weight, the process conditions, and the drying method. To reduce the initial burst and physical degradation (e.g. cracking), gp120 microspheres are preferably prepared with either a blend of high and low molecular weight PLGA or high molecular weight PLGA at low temperature without excess methylene chloride in the second emulsion. These microspheres can then be lyophilized or nitrogen dried to produce a free flowing powder.



Table 5: Effect of Drying Method on Initial Burst[a]

Polymer (lactide:glycolide)	Protein Loading[b] (% w/w)	Initial Burst (1 hr) [c] wet	lyophilized	nitrogen
12/100 kDa (50:50) BI [d]	3.1	16	19	12
	3.5	5	22	10
	1.8	15	15	10
	1.8	19	23	22
	0.5	2	0.4	1
18/100 kDa (50:50) MTI [d]	3.8	12	23	8
	3.9	9	32	17
	1.8	5	15	7
	1.8	7	13	4
100 kDa (50:50) MTI	1.8	10	10	2.4

a Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL protein solution/mL methylene chloride, reduced temperature, no excess methylene chloride in second emulsion).

b All preparations had greater than 95% encapsulation efficiency.

c The microspheres were analyzed for release of gp120 either after production while still wet or after drying by lyophilization , or nitrogen dried as described in Materials and Methods.

d A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

C. Correlation Between Second Burst and Polymer Properties

Microspheres were produced by using PLGA of varying composition (lactide:glycolide) and molecular weight to assess the differences in the timing of the second burst. To obtain an in vivo autoboost of gp120 at the desired appropriate time (e.g., 1, 2, 3, or 4 months), the microspheres are preferably designed to produce an in vitro second burst at the same time (37 °C, physiological buffer).

The in vitro release characteristics of each preparation was studied until 80 to 100% of the total protein was released from the microspheres. All the preparations displayed a characteristic release profile: initial burst, minimal release (less than 10%), and second burst. A typical release profile for MN rgp120 PLGA microspheres is shown in Figure 8. The release profile with the exception of the initial burst was not affected by the process conditions or drying, but the PLGA composition and molecular weight did have a significant impact. Bulk erosion of the microspheres is dependent upon the polymer composition (lactide:glycolide) and molecular weight and, therefore, the timing of the second burst resulting from bulk erosion is controlled by selecting the properties of the PLGA.

The in vitro release of MN rgp120 from PLGA microspheres correlates with the polymer properties as listed in Table 6. The microspheres produced from low molecular weight (12 or 18 kDa) PLGA with a 50:50 lactide:glycolide ratio had a second burst at 30 to 40 days, while microspheres made with the same molecular weight with a 75:25 lactide:glycolide ratio did not undergo bulk erosion and release protein until 60 to 75 days. A similar dependence between lactide content and second burst timing was also obtained for microspheres made from high molecular weight (100 kDa) PLGA. The microspheres made from 100 kDa PLGA had a second burst at 60 to 70 and 90 to 100 days for the 50:50 and 75:25 lactide:glycolide ratios, respectively. The equal mass ratio blends of low and high molecular weight PLGA underwent bulk erosion with subsequent protein release at the same time as the corresponding low molecular weight polymer alone (Table 6). Therefore, the addition of high molecular weight PLGA to the low molecular weight PLGA at an equal mass ratio does not affect the timing of the second burst, but it does improve the encapsulation efficiency and decrease the initial burst as shown above. Microspheres produced with an equal mass ratio of low and

high molecular weight PLGA should then be used if a one (50% lactide) or two (75% lactide) month autoboost is required. Alternatively, a two month autoboost can be obtained from microspheres made with the high molecular weight (100 kDa) PLGA with a 50:50 lactide:glycolide ratio. However, if a three month autoboost is needed, the microspheres could be produced with the high molecular weight (100 kDa) PLGA with a 75:25 lactide:glycolide ratio. These results confirm the previously observed relationship between in vivo degradation and polymer properties as depicted in Figure 2. Thus, if a later autoboost (4 to 6 months) is desired, then polylactic acid (PLA), a high molecular weight PLGA with a high lactide (greater than 50%) content, or a higher molecular weight PLGA with 50% lactide (greater than 0.75 dL/g) is preferably used.



Table 6: Correlation between PLGA Properties and Second Burst[a]

Polymer (lactide:glycolide)	Second Burst[b] Time (days)	% Released	Complete Erosion Time (days)
12 kDa (50:50) BI [c]	30-40	15	80
12 kDa (75:25) BI [c]	60-75	15	90
18 kDa (50:50) MTI	30-40	70	80
18 kDa (75:25) MTI	40-70	80	80
100 kDa (50:50) MTI [d]	60-70	50	100
100 kDa (75:25) MTI	90-100	85	120
12/100 kDa (50:50) BI [e]	30-40	80	80
12/100 kDa (75:25) BI [e]	60-70	70	110
18/100 kDa (50:50) MTI [e]	40-60	70	80

a Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL protein solution/mL methylene chloride, reduced temperature, no excess methylene chloride in second emulsion).

b Second burst from microspheres was usually observed over one to two weeks. The time range listed is the initial and final days when the percent released was significant (greater than 10%/wk). The % released is the sum of all the protein released during the second burst.

c These microspheres had a large initial burst (greater than 50%) and, therefore, the amount of protein remaining at the second burst was reduced.

d The preparation of these microspheres was performed at room temperature and excess methylene chloride (1.5%) was used in the second emulsion. These process changes resulted in a large initial burst.

e A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

Another consideration in choice of timing for the autoboost is the stability of the protein. Because the microspheres are fully hydrated after a short period of time (minutes to hours), the encapsulated protein will be in an aqueous environment at 37 °C. Degradation of the protein (with the exception of plasma-mediated proteolysis) can then occur in the microspheres. Previous studies have shown that MN rgp120 is stable at physiological conditions for at least four months. Therefore, to assure release of MN rgp120 that

is not degraded, an autoboost occurring within four months after injection is desirable.

D. Quality of MN rgp120 Released from PLGA Microspheres

Previous studies have indicated that it can be critical to maintain gp120 in the native conformation to obtain neutralizing antibodies (Steimer et al. Science 254:105-108, [1991]). Thus, several methods were used to completely characterize the state of the protein released from the microspheres.

As shown in Table 7, the amount of aggregated MN rgp120 was not significantly different for any of the formulations. The amount of aggregate was less than 7% for all the formulations. The type of polymer, drying method, and process conditions (temperature and excess methylene chloride) did not affect the amount of monomeric protein released from the microspheres in the initial burst. Also, the presence of the adjuvant, QS21, did not alter the amount of monomer released from the microspheres. The use of Tween® 20 in the QS21 phase (described below) yielded the same fraction of monomeric protein released from the microspheres. The studies of the relative hydrophobicity of the released protein by reverse phase chromatography revealed the same trend (Table 8). Again, the process did not affect the quality of the protein as measured by this technique.

Table 7: Effect of Microencapsulation on the Aggregation State of MN rgp120[a]

Polymer (lactide:glycolide)	Drying [b] Method	Process [c] Conditions	% Monomer [d]
Control - No Polymer	Aqueous	---	98
	Lyo.	---	96
12 kDa (50:50) BI	Vac.	0°C,-$MeCl_2$	96
	Lyo.		96
12 kDa (75:25) BI	Vac.	0°C,-$MeCl_2$	94
	Lyo.		94
18 kDa (50:50) MTI	Vac.	0°C,-$MeCl_2$	97
100 kDa (50:50) MTI	Vac.	RT,+$MeCl_2$	95
	Lyo.		95
	Nit.		96
100 kDa (75:25) MTI	Vac.	0°C,-$MeCl_2$	97
12/100 kDa (75:25) BI [e]	Vac.	RT,+$MeCl_2$	95
	Lyo.		97
12/100 kDa (75:25) BI [e]	Lyo.	0°C,+$MeCl_2$	97
12/100 kDa (75:25) BI [e]	Lyo.	0°C,-$MeCl_2$	97
18/100 kDa (50:50) MTI [e]	Vac.	RT,+$MeCl_2$	96
	Lyo.		95
18/100 kDa (50:50) MTI [e]	Lyo.	0°C,-$MeCl_2$	96
12/100 kDa (75:25) BI [e,f]	Lyo.	0°C,-$MeCl_2$	97
12 kDa (75:25) BI [g]	Lyo.	0°C,-$MeCl_2$	96

[a] Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL protein solution/mL methylene chloride).

[b] Microspheres were dried by either vacuum drying (Vac., 5°C for 1 week), lyophilization (Lyo.), or nitrogen drying (Nit.) as described in Materials and Methods.

[c] The microspheres were produced at either room temperature (RT) or 0° C and the second emulsion was either saturated with methylene chloride (+$MeCl_2$) or did not contain excess methylene chloride (-$MeCl_2$).

[d] The initial bursts from the microsphere preparations were analyzed by SEC-HPLC. The percent monomer and aggregate were defined as the relative peak areas of the main peak (monomer) and earlier eluting peaks (aggregates).

[e] A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

[f] Microspheres contained both QS21 and gp120 as described in the text.

[g] Microspheres contained QS21, Tween® 20, arginine and gp120 as discussed in the text.

Table 8: Effect of Microencapsulation on the Surface Hydrophobicity of MN rgp120[a]

Polymer (lactide/glycolide)	Drying[b] Method	Reverse Phase HPLC[c] % Main Peak
Control - No Polymer	Aqueous	98
	Lyo.	98
12 kDa (50:50) BI	Vac.	98
12 kDa (75:25) BI	Vac.	97
18 kDa (50:50) MTI	Vac.	98
100 kDa (75:25) MTI	Vac.	98
12/100 kDa (75:25) BI[d]	Lyo.	98
12/100 kDa (75:25) BI[d,e]	Lyo.	99
12 kDa (75:25) BI[f]	Lyo.	98

a Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL protein solution/mL methylene chloride, reduced temperature, no excess methylene chloride in second emulsion).

b Microspheres were dried by either vacuum drying (Vac., 5° C for 1 week) or lyophilization (Lyo.).

c Reversed phase HPLC analysis was performed on the MN rgp120 released in the initial burst (1 hr., 37 °C) from the microspheres. The protein eluted from the reverse phase column at two different times (minor and main peaks).

d A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

e Microspheres contained both QS21 and gp120 as described in the text.

f Microspheres contained QS21, Tween® 20, arginine and gp120 as detailed in the text.

The V3 loop region of MN rgp120 contains a proteolytic site. To assure that the V3 loop is maintained intact, the extent of V3 loop proteolysis was measured for protein released from the microspheres. As shown in Table 9, MN rgp120 released from the microspheres in the initial burst was more proteolytically degraded than the control which was maintained at 2 to 8° C and 2.3 mg/mL protein. However, the protein used for microencapsulation was concentrated from the control batch and stored at greater than 100 mg/mL for several months and this starting material also contained greater amounts of proteolytically degraded material. When

the MN rgp120 was concentrated, contaminating proteases could also have been concentrated. Storing starting material as a lyophilized formulation would avoid this difficulty. In general, MN rgp120 released from the microspheres in the initial burst is not significantly different from untreated starting protein as measured by several chromatographic methods.

Table 9: Assessment of Proteolysis for MN rgp120 Released from PLGA Microspheres[a]

Polymer (lactide:glycolide)	Drying[b] Method	% Clipping[c]
Control - No Polymer	Aqueous	3.0
	Lyo.	3.0
12 kDa (50:50) BI	Vac.	5.8
12 kDa (75:25) BI	Vac.	5.5
	Lyo.	8.0
18 kDa (50:50) MTI	Vac.	6.1
100 kDa (50:50) MTI	Vac.	6.1
	Lyo.	5.5
100 kDa (75:25) MTI	Vac.	3.4
12/100 kDa (75:25) BI[d]	Vac.	3.9
	Lyo.	3.2
18/100 kDa (50:50) MTI[d]	Vac.	6.1
	Lyo.	5.2
12 kDa (75:25) BI[e]	Lyo.	8.9

a Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL protein solution/mL methylene chloride, reduced temperature, no excess methylene chloride in second emulsion).

b Microspheres were dried by either vacuum drying (Vac., 5° C for 1 week) or lyophilization (Lyo.) as described in Materials and Methods.

c The initial bursts from the microsphere preparations were analyzed by SEC HPLC.

d A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

e Microspheres contained QS21, Tween® 20, arginine and gp120 as discussed in the text.

To assure that the protein released from the microspheres was maintained in its native conformation, several conformational assays were performed. First of all, the ability of the MN rgp120 released from the microspheres to bind antibodies against the whole protein and the V3 loop was assessed with ELISAs. The initial protein released from the microspheres had the same ability to bind both the total protein (Total MN) and V3 loop (V3) antibodies (Table 10, assay error ± 15%). The conformation of the released protein was also measured by circular dichroism (CD). Both the far ultraviolet and near ultraviolet CD spectra of MN rgp120 released from the microspheres were identical to the starting protein (Figure 9), indicating that the protein maintained both its secondary and tertiary structure. Subtle changes in conformation may not be observed by these methods and, therefore, CD4 binding analysis was performed on the released protein to assure intact conformation at this binding site. As shown in Table 11, the ability of MN rgp120 to bind CD4 is not altered by microencapsulation or lyophilization. Overall, the MN rgp120 released from the microspheres in the initial burst was not altered in its conformation and is expected to invoke an immune response equivalent to soluble protein.

Table 10: Analysis of Intact Epitopes for MN rgp120 Released from PLGA Microspheres[a]

Polymer (lactide:glycolide)	Drying Method [b]	ELISA Results (Normalized)[c] Total MN	V3
Control - No Polymer	Aqueous	100	100
	Lyo.	93	93
12 kDa (50:50) BI	Vac.	95	91
12 kDa (75:25) BI	Vac.	117	115
	Lyo.	102	97
18 kDa (50:50) MTI	Vac.	95	89
100 kDa (75:25) MTI	Vac.	92	89
12/100[d] kDa (75:25) BI	Lyo.	91	83
12/100[d] kDa (75:25) BI [e]	Lyo.	95	93
12 kDa (75:25) BI [f]	Lyo.	92	87

a Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL protein solution/mL methylene chloride, reduced temperature, no excess methylene chloride in second emulsion).

b Microspheres were dried by either vacuum drying (Vac., 5°C for 1 week) or lyophilization (Lyo.) as described in Materials and Methods.

c The initial bursts from the microsphere preparations were analyzed by ELISAs using either the whole protein (total MN rgp120) or a linear peptide of the V3 loop region (V3). Data were normalized to the control sample (aqueous formulation) and the standard error of the assay was ± 15%.

d A 50.50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

e Microspheres contained both QS21 and gp120 as described in the text.

f Microspheres contained QS21, Tween® 20, arginine and gp120 as detailed in the text.

Table 11: The Ability of MN rgp120 Released from PLGA Microspheres to bind CD4 [a]

Polymer (lactide:glycolide)	Drying [b] Method	CD4 Binding (Normalized) [c] (%)
Control - No Polymer	Aqueous	100.0
	Lyo.	114.3
12 kDa (75:25) BI	Vac.	88.9
100 kDa (50:50) MTI [d]	Vac.	85.7
12/100 kDa (75:25) BI [e]	Lyo.	117.2

a Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL protein solution/mL methylene chloride, reduced temperature, no excess methylene chloride in second emulsion).

b Microspheres were dried by either vacuum drying (Vac., 5° C for 1 week) or lyophilization (Lyo.) as described in Materials and Methods

c The initial bursts from the microsphere preparations were analyzed by competition assay for gp120 binding to CD4-IgG. The data were normalized to standards run on the same microtiter plate (% Binding=Sample/Standard *100%). The average error in these data was ± 23%.

d The preparation of these microspheres was performed at room temperature and excess methylene chloride (1.5%) was used in the second emulsion

e A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

E. Development of Encapsulated QS21 Formulations

The coencapsulation of QS21 and MN rgp120 required changes in the process parameters. Because the aqueous to organic volume ratio affects the encapsulation efficiency and initial burst (Equation 1), the ratio could not be increased to compensate for the additional QS21 solution. A formulation of QS21 at 200 mg/mL in 50% ethanol was used in combination with 114 mg/mL MN rgp120 (20 mM Tris, 120 mM NaCl, pH 7.4) for the inner aqueous phase. By using these concentrated solutions, the aqueous to organic volume ratio was maintained constant (0.1 mL/mL) and moderate theoretical loadings were achieved (2 to 5% w/w). The QS21 phase was injected into the polymer phase and then the protein solution was added to avoid direct contact between the QS21/ethanol

and MN rgp120 solutions prior to encapsulation. Microspheres prepared by this method with a 50:50 ratio of low (12 kDa) and high (100 kDa) molecular weight PLGA resulted in 100% encapsulation efficiency for the protein and only a 61.3% encapsulation efficiency for the QS21 (Table 12). Without limitation to any one theory, it is believed that the lower encapsulation efficiency for the QS21 could be the result of its surfactant properties. QS21 could accumulate at the aqueous/organic interface resulting in losses during the formation of the second emulsion and the final processing steps (hardening and washing). To reduce this possibility, 1% Tween® 20 was added to the QS21/ethanol formulation. Tween® is expected also to accumulate at the aqueous/organic interface and it is likely that Tween® will stabilize QS21 micelles. The QS21 encapsulation efficiency for microspheres produced by the same method with QS21/Tween®/ethanol was 80.6%. The addition of Tween® to the QS21 phase provided increased efficiency without adversely affecting the gp120 loading efficiency (100%). A completely efficient process for QS21 and gp120 coencapsulation was achieved with 20% Tween® in the QS21 phase and 12 kDa (75:25 lactide:glycolide) PLGA (Table 12).

To assess the encapsulation efficiency of QS21 alone, microspheres were prepared with the QS21/ethanol aqueous phase and 12 kDa (75:25 lactide:glycolide) PLGA. The volume ratio of aqueous to organic phase was reduced by one half, which is equivalent to the volume of QS21 used in coencapsulation. The QS21 encapsulation efficiency at these conditions was 100% and, thus, a lower volume ratio produced the same increased efficiency as the addition of Tween®. Overall, QS21 can be coencapsulated with gp120 or encapsulated alone with a high efficiency (80 to 100%).

Table 12: Efficiency of Microencapsulation Processes for QS21-PLGA Microspheres[a]

Formulation	% Loading (w/w)[b]		Loading Efficiency (%)	
	QS21	MN rgp120	QS21	MN rgp120
12/100 kDa (75:25) [c]				
MN rgp120 + QS21	1.9	2.5	61.3	100
MN rgp120 + QS21 [d]	2.5	2.5	80.6	100
12 kDa (75:25)				
MN rgp120 + QS21 [e]	3.1	2.5	100	100
QS21 [f]	3.3	---	100	---

a Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL aqueous solution/mL methylene chloride, reduced temperature, no excess methylene chloride in second emulsion, lyophilized).

b The mass fraction loading of QS21 and MN rgp120 was determined by dissolution of the microspheres in 1 N NaOH. Subsequent analysis of the treated material is described in the Materials and Methods section.

c A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres.

d The QS21 phase in this formulation contained 1% Tween® 20.

e This formulation consisted of QS21, 20% Tween® 20, and 100 mM arginine in the QS21 aqueous phase injection (500 µl, see Materials and Methods).

f Microspheres produced at an aqueous to organic volume ratio of 0.05 mL/mL.

The microspheres were analyzed for the amount of the initial burst of QS21 and the effect of QS21 on the initial burst of MN rgp120. As shown in Table 13, the initial burst from lyophilized microspheres was less than 30% for both the QS21 and the MN rgp120. In addition, the coencapsulation of QS21 with rgp120 did not increase the initial burst of protein from the microspheres (see Tables 2 and 13). The protein released in the initial burst was also not altered in its physicochemical properties (Tables 7 to 11). These studies indicate that microspheres with QS21 or QS21 and MN rgp120 can be prepared without a large initial burst of

either antigen or adjuvant (less than 30%) and the integrity of the antigen is not compromised.

Table 13: Release of QS21 and MN rgp120 from PLGA Microspheres [a]

Formulation	Initial Burst (%)[b] QS21	MN rgp120	Second Burst [c] Time (days)
12/100 kDa (75:25) [d]			
MN rgp120 + QS21	19	29	60-75
MN rgp120 + QS21 [e]	24	21	60-75
12 kDa (75:25)			
MN rgp120 + QS21 [f]	17	24	60-70
QS21 [g]	18	--	60-70

a Microspheres were prepared as described in Materials and Methods (0.3 g PLGA/mL methylene chloride, 0.1 mL aqueous solution/mL methylene chloride, reduced temperature, no excess methylene chloride in second emulsion, lyophilized).

b The material released in the initial burst from the microspheres (1 hr., 37°C) was analyzed by RP HPLC to determine the amount of QS21 and gp120.

c The second burst occurred over 7 to 14 days and the criteria for second burst for QS21 was greater than 2% intact QS21 released (see text for details).

d A 50:50 mass ratio of the low and high molecular weight PLGA was used to produce these microspheres. The QS21 phase in this formulation contained 1% Tween® 20.

f This formulation consisted of QS21, 20% Tween® 20, and 100 mM arginine in the QS21 aqueous phase injection (500 µl, see Materials and Methods).

g Microspheres produced at an aqueous to organic volume ratio of 0.05 mL/mL.

Another consideration for the QS21 microsphere formulations is the timing of the in vivo autoboost. Microspheres containing QS21, or QS21 with MN rgp120, were incubated in physiological buffer at 37 °C to assess the time for release of the second burst. As shown in Table 13, the second burst occurred over the same time range for both these microspheres and microspheres containing rgp120 alone (Table 6). In addition, the QS21 released from the microspheres after incubation in physiological buffer at 37°C for 74 days was 25% intact. The amount of intact QS21 after the same time at the same conditions in solution would be less than

25% since the degradation rate of QS21 at pH 7.4 is twenty fold greater than pH 5.5 (40° C) and the amount of intact QS21 remaining after 74 days at pH 5.5 and 40° C is less than 50%. Thus, encapsulation of QS21 does not affect the timing of the second burst and can reduce the rate of QS21 degradation and clearance in vivo.

F. Immunogenicity of MN rgp120 Microspheres

To assess the autoboost properties of MN rgp120 PLGA microspheres *in vivo*, guinea pigs were immunized once subcutaneously with different doses of the same microsphere formulations. The microspheres were prepared from 12 kDa (75:25 lactide:glycolide) PLGA supplied by BI and had a protein loading of 2.4% (w/w) and an initial burst of 61% (lyophilized formulation). This formulation was observed to have an autoboost (second burst) between 30 to 65 days *in vitro*. The antigen dose and amount of protein released in the initial burst were based on the *in vitro* data for all experiments. The standard dose of antigen (30 µg) was also administered with 60 µg of aluminum hydroxide (Rehydragel™, hereinafter denoted alum).

Typically, alum-formulated MN rgp120 required repeated immunizations at the same dose (30 µg antigen, 60 µg alum) to achieve increases in antibody titer. After the initial immunization with alum-formulated MN rgp120, the antibody titer in guinea pigs decreased after 4 to 5 weeks. The antibody titers elicited by these formulations were measured from sera taken at various times after immunization (week 0) as shown in Figures 10 and 11. Animals administered the low-dose of total antigen (14 µg) with PLGA had lower anti-MN rgp120 titers than the alum group at weeks 4 and 6 since the PLGA formulation only released 8.5 µg initially (Figure 10). Between weeks 6 and 8, the anti-MN rgp120 titer in the low-dose PLGA group (14 µg antigen) increased to titers that were

two fold greater than the alum group. The moderate dose of encapsulated antigen (42 μg) elicited a similar timing of increased titer and the anti-MN rgp120 titers were three and six fold greater than the low-dose PLGA (14 μg antigen) and alum groups, respectively. These results indicate that the *in vivo* autoboost occurs between 6 and 8 weeks for this formulation, consistent with the observed *in vitro* autoboost at 30 to 65 days. A comparison of the alum and PLGA groups at the same antigen dose revealed that the *in vivo* autoboost provides a greater humoral response (anti-MN rgp120 and anti-V3) than a single dose of alum adjuvant, but PLGA did not appear to provide greater adjuvant properties than alum (Figures 10 and 11).

In addition, the differences in anti-MN rgp120 titers between the low- and moderate-dose PLGA groups at weeks 8 through 20 revealed that the amount of protein in the initial immunization (initial burst, 8.5 μg in low dose; 25 μg in moderate dose) had less of an impact on the immune response to the whole antigen (anti-MN rgp120) than the autoboost (5.5 μg in low-dose; 17 μg in moderate dose), which is equivalent to a second immunization (Figure 10). However, the amount of antigen in the initial immunization did have an impact on the anti-V3 titers. As shown in Figure 11, the anti-V3 titers of the low-dose PLGA group were lower than the other formulations prior to the *in vivo* autoboost.

The high-dose PLGA group had seven-fold higher anti-MN rgp120 titers and two-fold higher anti-V3 titers than the low-dose PLGA group at weeks 8 through 14. In the high-dose PLGA group, high initial anti-MN rgp120 titers were observed and the *in vivo* autoboost that occurred between 6 and 8 weeks did not provide a large increase in titer. This is consistent with previous observations that indicate that the initial titer should be allowed to decrease prior to subsequent immunization (Anderson, et al., J. Infectious

Diseases 160:960-969, [1989]). Otherwise the humoral response is effectively dampened by existing antibodies. The high dose PLGA formulation did however elicit an increase in the anti-V3 titers between weeks 6 and 8.

The anti-V3 response was less sensitive than the anti-MN rgp120 response to the dose of antigen administered (Figure 11). The anti-V3 titer decreased after 4 weeks in the alum group, whereas anti-V3 titers for the PLGA groups increased after 6 weeks. The anti-V3 titers for the PLGA groups were two to six fold greater than the titer for the alum group at 8 to 14 weeks. The observed increase in both anti-MN rgp120 and anti-V3 titers for the PLGA groups indicate that the antigen released in the *in vivo* autoboost is essentially intact (no clipping in V3 loop).

To further assess the effect of encapsulation on the humoral response to MN rgp120, guinea pigs were immunized with the same amount of total antigen and two different amounts of encapsulated antigen. One group was administered 15 μg of soluble MN rgp120 along with 15 μg of encapsulated MN rgp120 and the other group was immunized with 30 μg of encapsulated MN rgp120. The PLGA formulation used for these experiments was prepared from a 50:50 mass ratio of 12 kDa (75:25 lactide:glycolide) and 100 kDa (75:25 lactide:glycolide) PLGA. The final microspheres had a protein loading of 4.9% (w/w) with an initial burst of 32% (lyophilized formulation). A control group was immunized with 30 μg of antigen with 60 μg of alum (Rehydragel™).

As shown in Figures 12 and 13, the group immunized with 15 μg each of soluble and encapsulated MN rgp120 had the lowest humoral response (weeks 4 through 8). This group received a total initial immunization (soluble and initial burst) of 19.5 μg MN rgp120. The alum control group had two fold greater anti-MN rgp120 and anti-V3 titers than this

group at 4 to 8 weeks. In addition, the group immunized with the same antigen dose (30 μg) in the encapsulated formulation had five fold greater anti-MN rgp120 titers than the soluble/encapsulated mixed formulation group at weeks 4 through 8. The encapsulated MN rgp120 formulation only released 9 μg of antigen initially, which is significantly less than both the alum and soluble/encapsulated formulations. Therefore, the microencapsulation of MN rgp120 induced a greater immune response than the soluble antigen.

To assess the ability of QS21 to increase the observed immune response to MN rgp120-PLGA, two different formulations were tested. One group of animals was immunized with 30 μg of MN rgp120 in a PLGA formulation (12/100 kDa (75:25 lactide:glycolide), 4.9% w/w protein, 32% initial burst) which was combined with 50 μg of soluble QS21. Another group of animals was immunized with a formulation consisting of both MN rgp120 and QS21 encapsulated in the same microspheres. The microspheres with MN rgp120 and QS21 were produced with a 50:50 mass ratio of 12 kDa (75:25 lactide:glycolide) and 100 kDa (75:25 lactide:glycolide) PLGA. These microspheres had a protein loading of 2.5% (w/w) and a QS21 loading of 1.9% (w/w). The initial burst from these microspheres for protein and QS21 was 29% and 19%, respectively. The antibody titers of animals immunized with soluble QS21 and encapsulated MN rgp120 were four (anti-V3) to six (anti-MN rgp120) fold greater than titers of animals immunized with the encapsulated MN rgp120 alone (Figures 12 and 13). The amount of antigen released initially (9 μg) was the same for both of these groups since the same PLGA formulation was used. Therefore, soluble QS21 enhanced the immune response to encapsulated MN rgp120.

Since encapsulated MN rgp120 provided a greater immune response than soluble MN rgp120, additional enhancement in the immune response caused by the encapsulation of QS21 was

examined. Animals were immunized with the PLGA formulation containing both MN rgp120 and QS21. The total antigen and QS21 dosed in the PLGA formulation were 25 μg and 19 μg, respectively. Both of these total doses were lower than the soluble and encapsulated controls because the protein and QS21 loadings were lower in these microspheres. As shown in Figures 12 and 13, the antibody titers of the group immunized with encapsulated MN rgp120/QS21 were an order of magnitude greater than the encapsulated MN rgp120 (30 μg dose) and alum control (30 μg dose) groups. In addition, the encapsulated MN rgp120/QS21 formulation only released 7.3 μg of MN rgp120 and 3.6 μg of QS21 in the initial burst. Therefore, a lower dose of both antigen and adjuvant in the encapsulated form was capable of yielding an order of magnitude greater immune response than the soluble or alum-formulated antigen.

To determine if the humoral response to MN rgp120 was sufficient to neutralize the virus upon infection, sera from guinea pigs immunized with MN rgp120 were analyzed for virus neutralization by using MT4 T-lymphoid cells which are very sensitive to HIV infection. The sera were taken from five different groups of guinea pigs, each immunized with a different formulation: 30 μg antigen with 60 μg alum, 30 μg antigen in Complete Freund's Adjuvant (CFA), 60 μg antigen with 50 μg QS21, 30 μg antigen with 50 μg QS21 and 60 μg alum, and 30 μg encapsulated antigen with 50 μg soluble QS21. The PLGA formulation was prepared from 12 kDa (50:50) PLGA. The microspheres had a protein loading of 1% (w/w) with an initial burst of 80% (lyophilized formulation). The animals were immunized with these formulations at 0, 1, and 2 months. Animals receiving CFA were boosted with incomplete Freund's adjuvant (IFA). The sera samples taken at day 70 were analyzed for virus neutralization.

As shown in Table 14, the MN virus neutralization titers from the group immunized with the MN rgp120-PLGA formulation

and soluble QS21 were 50% greater than titers from the QS21/alum group and were 10 fold greater than the titers from the alum and CFA groups. The ALA-1 virus neutralization titer for the QS21/PLGA group was 60% lower than the QS21/alum group, but it was 8 fold higher than the alum group. The group immunized with the high antigen dose (60 μg) and soluble QS21 had the highest neutralization titers for both strains. However, the MN virus neutralization titer for the high-dose group was only slightly greater than the titers for the QS21/PLGA group. Therefore, MN rgp120 released from PLGA microspheres induced the formation of neutralizing antibodies to the MN and ALA-1 strains of HIV-1.

Table 14: Virus neutralization titers for sera from guinea pigs at day 70 after immunization with different formulations of MN rgp120 (30 μg MN rgp120/dose, immunizations at 0, 1, and 2 months).

Formulation	Virus Neutralization Titer of HIV-1 strains	
	MN strain	ALA-1 strain
Alum (60 μg)	325	2000
CFA [a]	200	25
QS21 (50 μg) [b]	3500	35000
QS21 (50 μg) + Alum (60 μg)	2200	25000
QS21 (50 μg) + PLGA[c]	3000	15000

[a] Complete Freund's adjuvant was prepared by emulsification with a syringe-to-syringe technique immediately prior to immunization.

[b] This group was immunized with 60 μg of MN rgp120 along with the soluble QS21.

[c] The encapsulated MN rgp120 (12 kDa (50:50) PLGA, 1% w/w MN rgp120) was mixed with soluble QS21 prior to immunization.

CLAIMS

1. A composition comprising poly(D-L-lactide-co-glycolide) (PLGA) microspheres encapsulating an antigen, wherein

the ratio of lactide to glycolide is from about 100:1 to 1:100 weight percent;

the inherent viscosity of PLGA polymers used in the microspheres is about 0.1 to 1.2 dL/g;

the median diameter of the microspheres is from about 20 to 100 μm; and

the antigen is released from the microspheres in a triphasic pattern, wherein about 0.5 to 95% of the antigen is released in an initial burst, about 0 to 50% is released over a period of about 1 to 180 days, and the remaining antigen is released in a second burst after about 1 to 180 days.

2. The composition of claim 1 wherein the antigen is an HIV polypeptide.

3. The composition of claim 2 wherein the HIV polypeptide is gp120.

4. The composition of claim 1 wherein the median diameter of the microspheres is about 30 μm.

5. The composition of claim 1 further comprising an adjuvant.

6. The composition of claim 5 wherein the adjuvant is encapsulated in the PLGA microspheres.

7. The composition of claim 5 wherein the adjuvant is coencapsulated with the antigen in the microspheres.

8. The composition of claim 5 wherein the adjuvant is QS21.

9. The composition of claim 1 further comprising a soluble antigen.

10. A composition for use as a vaccine comprising an antigen encapsulated in poly(D-L-lactide-co-glycolide) (PLGA) microspheres, and a soluble antigen.

11. A composition for use as a vaccine comprising about one to 100 antigens encapsulated in a mixture of about two to 50 poly(D-L-lactide-co-glycolide) (PLGA) microsphere populations, wherein

the ratio of lactide to glycolide is from about 100:1 to 1:100;

the inherent viscosity of PLGA polymers used in the microspheres is about 0.1 to 1.2 dL/g;

the median diameter of the microspheres is from about 20 to 100 μm; and

the antigen is released from the microspheres in a triphasic pattern, wherein about 0.5 to 95% of the antigen is released in an initial burst, about 0 to 50% is released over a period of about 1 to 180 days, and the remaining antigen is released in a second burst in one microsphere population after about 1 to 30 days, in a second microsphere population after about 30 to 90 days, and in additional microsphere populations after about 90 to 180 days.

12. The composition of claim 11, wherein each microsphere population encapsulates the same antigen.

13. A method for encapsulating antigen in microspheres, comprising

(a) dissolving poly(D-L-lactide-co-glycolide) (PLGA) polymer in an organic solvent to produce a solution;

(b) adding an antigen to the solution of (a) to produce a PLGA-antigen mixture comprising a first emulsion;

(c) adding the mixture of step (b) to an emulsification bath to produce microspheres comprising a second emulsion; and

(d) hardening the microspheres of step (c) to produce hardened microspheres comprising encapsulated antigen.

14. The method of claim 13 wherein the organic solvent is methylene chloride.

15. The method of claim 13 wherein the organic solvent is ethyl acetate.

16. The method of claim 13 wherein the organic solvent is a mixture of ethyl acetate and benzyl alcohol or acetone.

17. The method of claim 13 wherein the emulsification bath comprises a polyvinyl alcohol solution.

18. The method of claim 17 wherein the polyvinyl alcohol solution contains ethyl acetate.

19. The method of claim 13 wherein the antigen is a dry polypeptide.

20. The method of claim 13 wherein the antigen is aqueous.

21. The method of claim 13 further comprising drying the hardened microspheres.

22. The method of claim 21, wherein the drying is selected from the group consisting of lyophilizing, fluidized bed drying, and vacuum drying.

Docket No. 825B

METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES

ABSTRACT OF THE DISCLOSURE

Methods and compositions are provided for the encapsulation of antigens in PLGA microspheres for use as vaccines. Such microspheres can also contain adjuvants. Mixtures of microspheres are provided which release antigen at desired intervals to provide boosts with antigen.


PLGA Microsphere
(Hydrated)
= water
Bulk Erosion
(Water, Temperature, Time)

Figure 1


Half-time to Complete Degradation (Months)
6
4
2
Increasing MW
0
PLA
100
100
PGA
0

Figure 2


Homogenization
speed
time
temperature
Protein Solution
volume
concentration
Polymer Solution
MeCl2 volume
polymer weight
polymer MW
Emulsification Conditions
speed
time
Emulsification Solution
PVA weight %
water volume
MeCl2 volume
temperature
Hardening Bath
volume
time
Diafiltration
wash volume
wash medium
Drying
Lyophilization
Release Studies

Figure 3


Nitrogen
Outlet
(c)
Cooling
Water
Inlet
(a) Slurry from
Diafiltration
(e) Dry Powder
Nitrogen
Inlet
(b)
10 µm
Mesh
Regulator
Cooling
Water
Outlet
(d)
Liquid
Outlet

Figure 4



Figure 5



Figure 6



Figure 7


% Release (Cumulative)
% Release (Daily)
Release Time (Days)
0
20
40
60
80
100
120
0
5
10
15
20
25
30
35
40

Figure 8


3000
0
-3000
-6000
-9000
-12000
MRW Ellipticity
198
208
218
228
238
248
Wavelength (nm)

Figure 9a


60
40
20
0
-20
-40
MRW Ellipticity
250
270
290
310
330
350
Wavelength (nm)

Figure 9b


40000
35000
30000
25000
20000
15000
10000
5000
0
Anti-MN gp120 Titers
-5
0
5
10
15
20
25
Time of Bleed (wks)

Figure 10


1400
1200
1000
800
600
400
200
0
Anti-V3 Titers
-5
0
5
10
15
20
25
Time of Bleed (wks)

Figure 11


1000000
100000
10000
1000
100
Anti-MN gp120 Titers
3
4
5
6
7
8
9
Time of Bleed (wks)

Figure 12



Figure 13

PATENT DOCKET P0825BC2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Rule 60 Continuation Application of

Jeffrey L. Cleland et al.

Serial No. 08/365,986

Filed: 28 DEC 1994

For: METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES

Prior Appln. Examiner: Julie Krsek-Staples, Ph.D.
Group Art Unit: 1813

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

May 22, 1995
(Date of Deposit)

Patricia Ferguson
Name of Depositing Party

Patricia Ferguson
Signature of Depositing Party

5/22/95
Date of Signature

ASSOCIATE POWER OF ATTORNEY (37 CFR 1.34)

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Please recognize as Associate Attorney in this case:

Jeffrey S. Kubinec, Reg. No. 36,575

Please direct all communications relative to said pending patent application to the following address:

Genentech, Inc.
460 Point San Bruno Boulevard
South San Francisco, CA 94080
Telephone: (415) 225-8228

Respectfully submitted,
GENENTECH, INC.

Date: May 22, 1995

By: Janet E. Hasak
Janet E. Hasak
Reg. No. 28,616

460 Pt. San Bruno Blvd.
So. San Francisco, CA 94080-4990
Phone: (415) 225-1896
Fax: (415) 952-9881

Docket No. 825B

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES

the specification of which (check one) __ is attached hereto or _x_ was filed on 25 October 1993 as Application Serial No. 08/143,555 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I hereby state that any Sequence Listing submitted with this application is submitted in paper copy and a computer-readable diskette, and that the content of the paper and computer readable copies are the same.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate have a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
			Yes	No
Number	Country	Day/Month/Year Filed		

I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned

---

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Walter E. Buting - Reg. No. 23,092
Renee A. Fitts - Reg. No. 35,136
Sean A. Johnston - Reg. No. 35,910
Daryl B. Winter - Reg. No. 32,637
Ginger R. Dreger - Reg. No. 33,055
Janet E. Hasak - Reg. No. 28,616
Stephen Raines - Reg. No. 25,912

Send correspondence to

Genentech, Inc.
Attn: Renee A. Fitts
460 Point San Bruno Boulevard
South San Francisco, CA 94080
Telephone: (415) 225-1489

I hereby declare that all statements made herein of my own knowledge and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from his foreign patent agent as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Full name of sole or first inventor

Jeffrey L. Cleland

Inventor's signature Jeffrey Lynn Cleland Date 12/23/93

Residence
844 Cordilleras Avenue, San Carlos, CA 94070

Citizenship
U.S.A.

Post Office Address
460 Point San Bruno Boulevard
South San Francisco, CA 94080

Full name of second joint inventor, if any

Amy Lim

Second Inventor's signature Amy Lim Date 1/4/94

Residence
2840 Berkshire Drive, San Bruno, CA 94066-1754

Citizenship
U.S.A.

Post Office Address
460 Point San Bruno Boulevard
South San Francisco, CA 94080

Full name of third joint inventor, if any

Michael Frank Powell

Third Inventor's signature Michael Frank Powell Date 1/10/94

Residence
531 Hugo Street, San Francisco, CA 94122

Citizenship
Canada

Post Office Address
460 Point San Bruno Boulevard
South San Francisco, CA 94080